JP3757986B2 - 上皮細胞増殖因子受容体に対するヒトモノクローナル抗体 - Google Patents

上皮細胞増殖因子受容体に対するヒトモノクローナル抗体 Download PDF

Info

Publication number
JP3757986B2
JP3757986B2 JP54839998A JP54839998A JP3757986B2 JP 3757986 B2 JP3757986 B2 JP 3757986B2 JP 54839998 A JP54839998 A JP 54839998A JP 54839998 A JP54839998 A JP 54839998A JP 3757986 B2 JP3757986 B2 JP 3757986B2
Authority
JP
Japan
Prior art keywords
sequence
antibody
human
egf
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP54839998A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001523973A5 (cg-RX-API-DMAC7.html
JP2001523973A (ja
Inventor
アヤ ジャコボビッツ
クシャオ−ドン ヤン
マイケル ギャロ
クシャオ−チ ジア
Original Assignee
アブジェニックス インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アブジェニックス インク． filed Critical アブジェニックス インク．
Publication of JP2001523973A publication Critical patent/JP2001523973A/ja
Publication of JP2001523973A5 publication Critical patent/JP2001523973A5/ja
Application granted granted Critical
Publication of JP3757986B2 publication Critical patent/JP3757986B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP54839998A 1997-05-05 1998-05-05 上皮細胞増殖因子受容体に対するヒトモノクローナル抗体 Expired - Lifetime JP3757986B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/851,362 US6235883B1 (en) 1997-05-05 1997-05-05 Human monoclonal antibodies to epidermal growth factor receptor
US08/851,362 1997-05-05
PCT/US1998/009160 WO1998050433A2 (en) 1997-05-05 1998-05-05 Human monoclonal antibodies to epidermal growth factor receptor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2005050969A Division JP2005225884A (ja) 1997-05-05 2005-02-25 上皮細胞増殖因子受容体に対するヒトモノクローナル抗体

Publications (3)

Publication Number Publication Date
JP2001523973A JP2001523973A (ja) 2001-11-27
JP2001523973A5 JP2001523973A5 (cg-RX-API-DMAC7.html) 2005-09-08
JP3757986B2 true JP3757986B2 (ja) 2006-03-22

Family

ID=25310591

Family Applications (9)

Application Number Title Priority Date Filing Date
JP54839998A Expired - Lifetime JP3757986B2 (ja) 1997-05-05 1998-05-05 上皮細胞増殖因子受容体に対するヒトモノクローナル抗体
JP2005050969A Withdrawn JP2005225884A (ja) 1997-05-05 2005-02-25 上皮細胞増殖因子受容体に対するヒトモノクローナル抗体
JP2008147230A Withdrawn JP2008273986A (ja) 1997-05-05 2008-06-04 上皮細胞増殖因子受容体に対するヒトモノクローナル抗体
JP2008276447A Withdrawn JP2009051861A (ja) 1997-05-05 2008-10-28 上皮細胞増殖因子受容体に対するヒトモノクローナル抗体
JP2010052859A Expired - Lifetime JP5356287B2 (ja) 1997-05-05 2010-03-10 上皮細胞増殖因子受容体に対するヒトモノクローナル抗体
JP2012104486A Withdrawn JP2012158601A (ja) 1997-05-05 2012-05-01 上皮細胞増殖因子受容体に対するヒトモノクローナル抗体
JP2014122089A Withdrawn JP2014185165A (ja) 1997-05-05 2014-06-13 上皮細胞増殖因子受容体に対するヒトモノクローナル抗体
JP2016149288A Withdrawn JP2017025064A (ja) 1997-05-05 2016-07-29 上皮細胞増殖因子受容体に対するヒトモノクローナル抗体
JP2017224446A Withdrawn JP2018076321A (ja) 1997-05-05 2017-11-22 上皮細胞増殖因子受容体に対するヒトモノクローナル抗体

Family Applications After (8)

Application Number Title Priority Date Filing Date
JP2005050969A Withdrawn JP2005225884A (ja) 1997-05-05 2005-02-25 上皮細胞増殖因子受容体に対するヒトモノクローナル抗体
JP2008147230A Withdrawn JP2008273986A (ja) 1997-05-05 2008-06-04 上皮細胞増殖因子受容体に対するヒトモノクローナル抗体
JP2008276447A Withdrawn JP2009051861A (ja) 1997-05-05 2008-10-28 上皮細胞増殖因子受容体に対するヒトモノクローナル抗体
JP2010052859A Expired - Lifetime JP5356287B2 (ja) 1997-05-05 2010-03-10 上皮細胞増殖因子受容体に対するヒトモノクローナル抗体
JP2012104486A Withdrawn JP2012158601A (ja) 1997-05-05 2012-05-01 上皮細胞増殖因子受容体に対するヒトモノクローナル抗体
JP2014122089A Withdrawn JP2014185165A (ja) 1997-05-05 2014-06-13 上皮細胞増殖因子受容体に対するヒトモノクローナル抗体
JP2016149288A Withdrawn JP2017025064A (ja) 1997-05-05 2016-07-29 上皮細胞増殖因子受容体に対するヒトモノクローナル抗体
JP2017224446A Withdrawn JP2018076321A (ja) 1997-05-05 2017-11-22 上皮細胞増殖因子受容体に対するヒトモノクローナル抗体

Country Status (16)

Country Link
US (1) US6235883B1 (cg-RX-API-DMAC7.html)
EP (3) EP1878746A3 (cg-RX-API-DMAC7.html)
JP (9) JP3757986B2 (cg-RX-API-DMAC7.html)
KR (1) KR100558110B1 (cg-RX-API-DMAC7.html)
AT (1) ATE366747T1 (cg-RX-API-DMAC7.html)
AU (1) AU7287098A (cg-RX-API-DMAC7.html)
CA (1) CA2288962C (cg-RX-API-DMAC7.html)
CY (2) CY1107708T1 (cg-RX-API-DMAC7.html)
DE (2) DE69838062T2 (cg-RX-API-DMAC7.html)
DK (1) DK0979246T3 (cg-RX-API-DMAC7.html)
ES (1) ES2289779T3 (cg-RX-API-DMAC7.html)
FR (1) FR08C0006I2 (cg-RX-API-DMAC7.html)
LU (1) LU91411I2 (cg-RX-API-DMAC7.html)
NL (1) NL300335I2 (cg-RX-API-DMAC7.html)
PT (1) PT979246E (cg-RX-API-DMAC7.html)
WO (1) WO1998050433A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1066)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5632296A (en) * 1995-04-27 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US20050241006A1 (en) * 1995-04-27 2005-10-27 Abgenix, Inc. Human antibodies derived from immunized xenomice
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US20050287630A1 (en) * 1995-04-27 2005-12-29 Abgenix, Inc. Human antibodies derived from immunized xenomice
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US20020173629A1 (en) * 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
US6358508B1 (en) * 1997-06-11 2002-03-19 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR9
US6417168B1 (en) * 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
US7067144B2 (en) * 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
KR100617337B1 (ko) * 1998-12-23 2006-08-31 화이자 인크. Ｃｔｌａ－４에 대한 인간 단일클론 항체
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
JP2002537769A (ja) 1999-02-26 2002-11-12 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ヒトエンドカインαおよび使用方法
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
PL365999A1 (en) * 1999-05-14 2005-01-24 Imclone Systems Incorporated Treatment of refractory human tumors with epidermal growth factor receptor antagonists
WO2001000245A2 (en) 1999-06-25 2001-01-04 Genentech, Inc. HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES
ES2282133T3 (es) 1999-08-24 2007-10-16 Medarex, Inc. Anticuerpos frente a la ctla-4 humano y sus usos.
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
WO2002043660A2 (en) 2000-11-28 2002-06-06 Mediummune, Inc Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
GB0002952D0 (en) * 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
EP1257585A2 (en) 2000-02-10 2002-11-20 Basf Aktiengesellschaft Antibodies that bind human interleukin-18 and methods of making and using
EP1983055A1 (en) 2000-04-12 2008-10-22 Human Genome Sciences, Inc. Albumin fusion proteins
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
WO2001096528A2 (en) 2000-06-15 2001-12-20 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
WO2002002641A1 (en) 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
CA2418083A1 (en) * 2000-08-09 2002-02-14 Imclone Systems Incorporated Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
GEP20084484B (en) 2001-01-05 2008-09-25 Pfizer Antibodies to insulin-like growth factor i receptor
CN1564826A (zh) 2001-02-09 2005-01-12 人类基因组科学公司 人类g蛋白趋化因子受体(ccr5)hdgnr10
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
WO2002083704A1 (en) 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
EP1392359B2 (en) 2001-05-11 2013-03-13 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
WO2002092017A2 (en) 2001-05-16 2002-11-21 Albert Einstein College Of Medicine Of Yeshiva University Human antipneumococcal antibodies from non-human animals
US7595378B2 (en) * 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
MXPA03011365A (es) * 2001-06-13 2005-03-07 Genmab As Anticuerpos monoclonales humanos para el receptor de factor de crecimiento epidermico (egfr).
US6867189B2 (en) 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
AU2002357932A1 (en) * 2001-12-18 2003-06-30 Whitehead Institute For Biomedical Research Fusion partner cells and uses thereof
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
US20080063639A1 (en) * 2002-01-18 2008-03-13 Pierre Fabre Medicament Method for the treatment of psoriasis comprising novel anti-IGF-IR antibodies
US20080193445A1 (en) * 2002-01-18 2008-08-14 Liliane Goetsch Novel anti-IGF-IR antibodies and uses thereof
US7662925B2 (en) * 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EP1497444B1 (en) 2002-03-27 2015-11-04 Immunex Corporation Methods for increasing polypeptide production
DK1527100T3 (da) 2002-03-29 2009-09-07 Schering Corp Humane monoklonale antistoffer mod interleukin-5 og fremgangsm der og sammens tninger omfattende samme
WO2003086458A1 (en) 2002-04-12 2003-10-23 Medimmune, Inc. Recombinant anti-interleukin-9 antibodies
WO2003086459A1 (en) 2002-04-12 2003-10-23 Medarex, Inc. Methods of treatement using ctla-4 antibodies
CA2485691A1 (en) * 2002-05-20 2003-12-04 Abgenix, Inc. Treatment of renal carcinoma using antibodies against the egfr
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US20040022792A1 (en) * 2002-06-17 2004-02-05 Ralph Klinke Method of stabilizing proteins at low pH
WO2004000102A2 (en) * 2002-06-19 2003-12-31 Abgenix, Inc. Method for predicting response to epidermal growth factor receptor-directed therapy
CN101711866A (zh) 2002-07-15 2010-05-26 健泰科生物技术公司 鉴定对用抗ErbB2抗体处理响应的肿瘤的方法
EP1534335B9 (en) 2002-08-14 2016-01-13 Macrogenics, Inc. Fcgammariib-specific antibodies and methods of use thereof
EP2298805A3 (en) 2002-09-27 2011-04-13 Xencor, Inc. Optimized Fc variants and methods for their generation
DK2891666T3 (en) 2002-10-16 2017-10-02 Purdue Pharma Lp Antibodies that bind cell-associated CA 125 / O722P and methods for its use
GB0304367D0 (en) * 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
CA2501077C (en) * 2002-11-12 2016-06-21 Gerald B. Pier Polysaccharide vaccine for staphylococcal infections
US20040147428A1 (en) * 2002-11-15 2004-07-29 Pluenneke John D. Methods of treatment using an inhibitor of epidermal growth factor receptor
US20040214203A1 (en) * 2002-12-12 2004-10-28 Oncotech, Inc. Genes related to sensitivity and resistance to chemotherapeutic drug treatment
EP1581171B1 (en) 2002-12-20 2012-06-27 Abbott Biotherapeutics Corp. Antibodies against gpr64 and uses thereof
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
EP1585815A4 (en) 2003-01-21 2006-02-22 Bristol Myers Squibb Co A NEW ACYL-COENZYME A, MONOCLYLGLYCERIN ACYLTRANSFERASE-3 (MGAT3), CODING POLYNUCLEOTIDE, AND USES THEREOF
WO2005011619A2 (en) * 2003-01-31 2005-02-10 Five Prime Therapeutics, Inc. Lung-expressed polypeptides
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7662387B2 (en) 2003-02-20 2010-02-16 Seattle Genetics Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US8388955B2 (en) * 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20090010920A1 (en) * 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
ES2537015T3 (es) 2003-03-19 2015-06-01 Biogen Ma Inc. Proteína de unión del receptor de NOGO
JP4764818B2 (ja) 2003-04-11 2011-09-07 メディミューン，エルエルシー 組換えｉｌ−９抗体およびその使用
KR20060003882A (ko) * 2003-04-14 2006-01-11 더 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 하이브리도마 부재하의 폴리클로날 및 모노클로날 항체의생체외 제조 및 불멸화된 세포 집단의 생성 방법
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
EP2389953A1 (en) 2003-06-09 2011-11-30 Samuel Waksal Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular antagonist
JP4808614B2 (ja) * 2003-06-27 2011-11-02 アムジエン・フレモント・インコーポレイテツド 上皮成長因子受容体の欠失型変異体を認識する抗体、およびそれらの使用
US7393534B2 (en) 2003-07-15 2008-07-01 Barros Research Institute Compositions and methods for immunotherapy of cancer and infectious diseases
US7619059B2 (en) 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes
CA2445420A1 (en) 2003-07-29 2005-01-29 Invitrogen Corporation Kinase and phosphatase assays
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
WO2005014795A2 (en) 2003-08-08 2005-02-17 Genenews Inc. Osteoarthritis biomarkers and uses thereof
GB0321066D0 (en) * 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
US8101720B2 (en) * 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
KR101438983B1 (ko) 2003-11-06 2014-09-05 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
US7371381B2 (en) 2003-12-12 2008-05-13 Amgen Inc. Anti-galanin antibodies and uses thereof
DK2805728T3 (da) 2003-12-23 2020-04-20 Genentech Inc Hidtil ukendte anti-IL13-antistoffer og anvendelser deraf
EP1759010A4 (en) * 2004-01-07 2008-12-24 Bristol Myers Squibb Co BIOMARKERS AND METHOD FOR DETERMINING SENSITIVITY AGAINST MODULATORS OF EGF (EPIDERMAL GROWTH FACTOR) RECEPTORS
MX350383B (es) 2004-01-09 2017-09-04 Pfizer Anticuerpos contra madcam.
CN1950518A (zh) 2004-02-03 2007-04-18 密执安州立大学董事会 表征、调节、诊断和治疗癌症的组合物和方法
AU2005211725B2 (en) 2004-02-09 2010-07-15 Human Genome Sciences, Inc. Albumin fusion proteins
TW200533339A (en) * 2004-03-16 2005-10-16 Bristol Myers Squibb Co Therapeutic synergy of anti-cancer compounds
ES2387809T3 (es) * 2004-03-19 2012-10-02 Imclone Llc Anticuerpo frente al receptor del factor de crecimiento epidérmico humano
US7625549B2 (en) * 2004-03-19 2009-12-01 Amgen Fremont Inc. Determining the risk of human anti-human antibodies in transgenic mice
WO2005097832A2 (en) 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies
US20060034840A1 (en) 2004-04-08 2006-02-16 Agus David B ErbB antagonists for pain therapy
PT1745075E (pt) * 2004-04-21 2013-06-17 Brigham & Womens Hospital Péptidos de ligação a poli-n-acetilglucosamina (pnag/dpnag) e métodos da sua utilização
TW200607523A (en) 2004-06-01 2006-03-01 Domantis Ltd Drug compositions, fusions and conjugates
RU2404810C9 (ru) 2004-06-01 2015-06-20 Дженентек, Инк. Конъюгаты антитело-лекарственное средство и способы
EP3332803B1 (en) 2004-06-01 2021-09-08 Icahn School of Medicine at Mount Sinai Genetically engineered swine influenza virus and uses thereof
PL1776136T3 (pl) 2004-06-24 2013-03-29 Biogen Ma Inc Leczenie stanów związanych z demielinizacją
JP2008505174A (ja) 2004-07-15 2008-02-21 ゼンコー・インコーポレイテッド 最適化Ｆｃ変異体
EP1802341A1 (en) 2004-07-16 2007-07-04 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
WO2006017673A2 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
DK2319925T3 (da) 2004-08-16 2018-11-05 Quark Pharmaceuticals Inc Terapeutiske anvendelser af RTP801-hæmmere
CA2486285C (en) 2004-08-30 2017-03-07 Viktor S. Goldmakher Immunoconjugates targeting syndecan-1 expressing cells and use thereof
JP2008513540A (ja) 2004-09-21 2008-05-01 メディミューン，インコーポレーテッド 呼吸器合胞体ウイルスに対する抗体及び該ウイルス用のワクチンを製造する方法
CN104447992A (zh) 2004-09-23 2015-03-25 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP2008518023A (ja) 2004-10-27 2008-05-29 メディミューン，インコーポレーテッド 同族抗原に対する親和性を改変することによる抗体特異性の調節
US20070135620A1 (en) * 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
BRPI0517837A (pt) 2004-11-12 2008-10-21 Xencor Inc variantes fc com ligação alterada a fcrn
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
SG157423A1 (en) 2004-12-02 2009-12-29 Domantis Ltd Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
KR20130089280A (ko) 2005-01-21 2013-08-09 제넨테크, 인크. Ｈｅｒ 항체의 고정 용량 투여법
CN103497993A (zh) 2005-02-07 2014-01-08 基因信息公司 轻度骨关节炎生物标志物及其用途
DK1853718T3 (en) 2005-02-15 2015-11-09 Univ Duke ANTI-CD19 ANTIBODIES AND THEIR USE IN ONCOLOGY
US20060188498A1 (en) * 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
US20090155247A1 (en) * 2005-02-18 2009-06-18 Ashkenazi Avi J Methods of Using Death Receptor Agonists and EGFR Inhibitors
ES2440481T3 (es) 2005-02-23 2014-01-29 Genentech, Inc. Prolongación del tiempo hasta la progresión de la enfermedad o supervivencia en pacientes de cáncer de ovario usando pertuzumab
US20090136505A1 (en) * 2005-02-23 2009-05-28 Johanna Bentz Intranasal Administration of Active Agents to the Central Nervous System
WO2006096565A2 (en) 2005-03-04 2006-09-14 Curedm Inc. Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
DK2620450T3 (en) 2005-03-08 2019-02-04 Pfizer Prod Inc Antibody Compositions against CTLA-4
US20060216288A1 (en) * 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
ES2707152T3 (es) 2005-04-15 2019-04-02 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
KR100680141B1 (ko) * 2005-04-20 2007-02-07 주식회사 녹십자 항-ｅｇｆ 수용체 단일클론항체 및 이를 생산하는하이브리도마 세포주
MX2007013217A (es) 2005-04-25 2008-03-11 Pfizer Anticuerpos contra miostatina.
UA95775C2 (uk) 2005-04-26 2011-09-12 Пфайзер Инк. Антитіло, яке специфічно зв'язується з р-кадгерином
PA8672101A1 (es) 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
AU2006244445B2 (en) 2005-05-05 2013-04-18 Duke University Anti-CD19 antibody therapy for autoimmune disease
EP1888649A2 (en) * 2005-05-09 2008-02-20 GlycArt Biotechnology AG Antigen binding molecules having modified fc regions and altered binding to fc receptors
AR053272A1 (es) 2005-05-11 2007-04-25 Hoffmann La Roche Determinacion de responsivos a la quimioterapia
WO2006128083A2 (en) 2005-05-25 2006-11-30 Curedm, Inc. Human proislet peptide, derivatives and analogs thereof, and methods of using same
GB0510790D0 (en) 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
WO2007002543A2 (en) 2005-06-23 2007-01-04 Medimmune, Inc. Antibody formulations having optimized aggregation and fragmentation profiles
PL1896073T3 (pl) 2005-06-30 2013-08-30 Janssen Biotech Inc Przeciwciała anty-IL-23, kompozycje, sposoby i zastosowania
ES2434470T3 (es) 2005-07-08 2013-12-16 Biogen Idec Ma Inc. Anticuerpos SP35 y usos de éstos
EP1904652A2 (en) 2005-07-08 2008-04-02 Brystol-Myers Squibb Company Single nucleotide polymorphisms associated with dose-dependent edema and methods of use thereof
AU2006275475A1 (en) * 2005-07-29 2007-02-08 Amgen Inc. Formulations that inhibit protein aggregation
ES2579602T3 (es) 2005-08-10 2016-08-12 Macrogenics, Inc. Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de uso de estos
NZ597168A (en) 2005-08-19 2013-07-26 Abbott Lab Dual variable domain immunoglobin and uses thereof
EP2500358A3 (en) 2005-08-19 2012-10-17 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20090215992A1 (en) * 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
WO2007025044A2 (en) * 2005-08-24 2007-03-01 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
AP2013006963A0 (en) 2005-09-07 2013-07-31 Amgen Fremont Inc Human monoclonal antibodies to activin receptor-like Kinase-1
WO2007039256A2 (de) 2005-09-30 2007-04-12 Abbott Gmbh & Co. Kg Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
EP1931709B1 (en) 2005-10-03 2016-12-07 Xencor, Inc. Fc variants with optimized fc receptor binding properties
WO2007048074A1 (en) 2005-10-21 2007-04-26 Genenews Inc. Method and apparatus for correlating levels of biomarker products with disease
KR20080080109A (ko) 2005-11-04 2008-09-02 바이오겐 아이덱 엠에이 인코포레이티드 도파민성 뉴런의 신경돌기 성장 및 생존의 촉진 방법
NZ567483A (en) 2005-11-04 2012-04-27 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases
WO2007056352A2 (en) 2005-11-07 2007-05-18 The Scripps Research Institute Compositions and methods for controlling tissue factor signaling specificity
ATE461220T1 (de) 2005-11-12 2010-04-15 Lilly Co Eli Anti-egfr-antikörper
PT1954718E (pt) 2005-11-30 2014-12-16 Abbvie Inc Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
NZ595736A (en) 2005-12-02 2013-05-31 Sinai School Medicine Chimeric viruses presenting non-native surface proteins and uses thereof
AU2006320479B2 (en) 2005-12-02 2012-11-08 Biogen Ma Inc. Treatment of conditions involving demyelination
NZ568016A (en) 2005-12-07 2011-12-22 Medarex Inc CTLA-4 antibody dosage escalation regimens
US10183986B2 (en) 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
AR056857A1 (es) * 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
NL2000439C2 (nl) 2006-01-20 2009-03-16 Quark Biotech Therapeutische toepassingen van inhibitoren van RTP801.
EP2526968A3 (en) 2006-01-27 2013-05-22 Biogen Idec MA Inc. Nogo receptor antagonists
SG10201504662WA (en) 2006-06-14 2015-07-30 Macrogenics Inc Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity
CA2656222C (en) 2006-06-26 2018-07-17 Macrogenics, Inc. Fc.gamma.riib-specific antibodies and methods of use thereof
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
AU2007274738B2 (en) 2006-07-18 2013-11-28 Sanofi-Aventis Antagonist antibody against EphA2 for the treatment of cancer
CN101522717A (zh) 2006-08-04 2009-09-02 阿斯利康(瑞典)有限公司 针对ErbB2的人抗体
TWI405771B (zh) 2006-08-28 2013-08-21 Kyowa Hakko Kirin Co Ltd 具拮抗性之人類ｌｉｇｈｔ專一性人類單株抗體
MY161894A (en) 2006-09-08 2017-05-15 Abbvie Bahamas Ltd Interleukin-13 binding proteins
ES2372217T3 (es) 2006-09-12 2012-01-17 Genentech, Inc. Procedimientos y composiciones para el diagnóstico y tratamiento del cáncer de pulmón utilizando el gen de pdgfra, kit o kdr como marcador genético.
CL2007002880A1 (es) * 2006-10-06 2008-05-09 Amgen Inc Formulacion estable que comprende un tampon de acido acetico, un tampon de acido glutamico o un tampon de acido succinico con un ph de 4,5 a 7, por lo menos un excipiente que comprende un azucar o un poliol, y un anticuerpo anti-receptor del factor d
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
EP2407548A1 (en) 2006-10-16 2012-01-18 MedImmune, LLC Molecules with reduced half-lives, compositions and uses thereof
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
TW200833357A (en) * 2006-10-20 2008-08-16 Amgen Inc Stable polypeptide formulations
US8785400B2 (en) 2006-11-22 2014-07-22 Curedm Group Holdings, Llc Methods and compositions relating to islet cell neogenesis
FR2909092B1 (fr) * 2006-11-24 2012-10-19 Pf Medicament Nouveaux anticorps anti-proliferation
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
CN101678100A (zh) 2006-12-06 2010-03-24 米迪缪尼有限公司 治疗系统性红斑狼疮的方法
AU2007333805B2 (en) 2006-12-18 2013-07-25 Genentech, Inc. Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-related diseases
WO2008079982A2 (en) * 2006-12-21 2008-07-03 Centocor, Inc. Liposome composition for targeting egfr receptor
US8536113B2 (en) * 2006-12-21 2013-09-17 Janssen Biotech, Inc. EGFR binding peptides and uses thereof
US8278415B2 (en) 2006-12-21 2012-10-02 Centocor, Inc. Dimeric high affinity EGFR constructs and uses thereof
CA2671585A1 (en) * 2006-12-22 2008-07-03 Novelix Therapeutics Gmbh Treatment of diabetes by at least one epidermal growth factor receptor specific antibody or a derivative thereof
HUE034512T2 (en) 2007-01-05 2018-02-28 Univ Zuerich A method for providing disease-specific binding molecules and targets
CN103360495B (zh) 2007-01-09 2016-06-08 比奥根Ma公司 Sp35抗体及其用途
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
WO2008088823A2 (en) 2007-01-16 2008-07-24 Abbott Laboratories Methods for treating psoriasis
US9090693B2 (en) 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
KR20080074683A (ko) * 2007-02-09 2008-08-13 삼성전자주식회사 디지털 저작권 관리 방법 및 장치
WO2008101184A2 (en) 2007-02-16 2008-08-21 The Board Of Trustees Of Southern Illinois University Arl-1 specific antibodies
US8685666B2 (en) 2007-02-16 2014-04-01 The Board Of Trustees Of Southern Illinois University ARL-1 specific antibodies and uses thereof
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
AU2008221118B2 (en) * 2007-03-01 2013-10-03 Les Laboratoires Servier Recombinant anti-epidermal growth factor receptor antibody compositions
EP2899541A1 (en) 2007-03-02 2015-07-29 Genentech, Inc. Predicting response to a HER dimerisation inhbitor based on low HER3 expression
RS53265B2 (sr) 2007-03-13 2022-06-30 Amgen Inc K-ras mutacije i terapija anti-egfr antitelom
PE20090690A1 (es) 2007-03-13 2009-06-22 Amgen Inc Mutaciones de k-ras y b-raf y terapia con anticuerpos anti-egfr
CN101688229B (zh) 2007-03-15 2013-06-12 路德维格癌症研究所 包含egfr抗体和src抑制剂的组合物及其在制备用于治疗哺乳动物癌症的药物中的用途
WO2008118324A2 (en) 2007-03-26 2008-10-02 Macrogenics, Inc. Composition and method of treating cancer with an anti-uroplakin ib antibody
JP5456658B2 (ja) 2007-03-30 2014-04-02 メディミューン，エルエルシー 抗体製剤
CA2682927A1 (en) 2007-04-02 2008-10-16 Amgen Fremont Inc. Anti-ige antibodies
PT2068927E (pt) 2007-05-14 2016-02-10 Medimmune Llc Métodos para reduzir os níveis de eosinófilos
PL2171090T3 (pl) 2007-06-08 2013-09-30 Genentech Inc Markery ekspresji genów odporności guza na leczenie hamujące HER2
EP2158221B1 (en) 2007-06-21 2018-08-29 MacroGenics, Inc. Covalent diabodies and uses thereof
WO2008154927A1 (en) * 2007-06-21 2008-12-24 Genmab A/S Novel methods for treating egfr-associated tumors
CN101896503B (zh) 2007-08-14 2018-05-22 路德维格癌症研究所有限公司 靶向egf受体的单克隆抗体175及其衍生物和用途
JP6035009B2 (ja) 2007-08-22 2016-11-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用
PT2195023T (pt) 2007-08-29 2018-06-08 Sanofi Sa Anticorpos anti-cxcr5 humanizados, seus derivados e suas utilizações
NZ599756A (en) 2007-08-30 2013-09-27 Curedm Group Holdings Llc Compositions and methods of using proislet peptides and analogs thereof
ES3006441T3 (en) 2007-09-14 2025-03-18 Amgen Inc Homogeneous antibody populations
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US7985559B2 (en) 2007-10-19 2011-07-26 Amgen Inc. Methods of selecting epidermal growth factor receptor (EGFR) binding agents
US8663980B2 (en) 2007-10-26 2014-03-04 Janssen Biotech, Inc. Vectors, host cells, and methods of production and uses
WO2009061818A1 (en) 2007-11-05 2009-05-14 Medimmune, Llc Methods of treating scleroderma
WO2009070642A1 (en) 2007-11-28 2009-06-04 Medimmune, Llc Protein formulation
BRPI0821449A2 (pt) 2007-12-26 2015-06-16 Biotest Ag Imunoconjugado, métodos para tratar mieloma múltiplo em um indíviduo, para dispensar medicamento mediado por imunoconjugado, para inibir, atrasar e/ou evitar o desenvolvimento de um tumor e/ou dispensar células tumorais malignas em um paciente em necessidade do mesmo, para tratar um indíviduo tendo uma condição e opara diminuir uma quantidade de células em contato direto ou indireto com as imunoconjugado, método para tratar mieloma múltiplo em um indivíduo, para dispensar medicamento mediado por imunoconjugado, para inibir, atrasar e/ou evitar o desenvolvimento de células tumorais em uma cultura celular, para inibir, atrasar e/ou evitar o desenvolvimento de um tumor e/ou dispensar células tumorais malignas em um paciente em necessidade do mesmo, para tratar um indivíduo tendo uma condição e para diminuir uma quantidade de células em contato direto ou indireto com as células tumorais, composição farmacêutica, e, kit.
JP5690593B2 (ja) 2007-12-26 2015-03-25 ヴァクシネックス， インコーポレイテッド 抗ｃ３５抗体併用療法および方法
SI2238168T1 (sl) 2007-12-26 2014-09-30 Biotest Ag Sredstva, ki ciljajo CD138, in njihove uporabe
EP2238169A1 (en) 2007-12-26 2010-10-13 Biotest AG Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
US9446146B2 (en) 2007-12-26 2016-09-20 Biotest Ag Methods and agents for improving targeting of CD138 expressing tumor cells
PL2808343T3 (pl) 2007-12-26 2019-11-29 Xencor Inc Warianty Fc ze zmienionym wiązaniem do FcRn
US8557242B2 (en) * 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8557243B2 (en) * 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8454960B2 (en) * 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US20110033378A1 (en) 2008-01-18 2011-02-10 Medlmmune, Llc. Cysteine Engineered Antibodies For Site-Specific Conjugation
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
AU2009209541A1 (en) * 2008-01-30 2009-08-06 Pharma Mar, S.A. Improved antitumoral treatments
EP2250279B1 (en) 2008-02-08 2016-04-13 MedImmune, LLC Anti-ifnar1 antibodies with reduced fc ligand affinity
US12492253B1 (en) 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
CA2717117A1 (en) * 2008-03-07 2009-09-11 Pharma Mar, S.A. Improved antitumoral treatments
EP2810954A3 (en) 2008-03-18 2015-03-18 Abbvie Inc. Methods for treating psoriasis
WO2009118300A1 (en) 2008-03-25 2009-10-01 Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating cancer by down-regulating frizzled-4 and/or frizzled-1
WO2009120922A2 (en) 2008-03-27 2009-10-01 Zymogenetics, Inc. Compositions and methods for inhibiting pdgfrbeta and vegf-a
TW201002346A (en) * 2008-04-11 2010-01-16 Galaxy Biotech Llc Combination of HGF inhibitor and EGF inhibitor to treat cancer
CN102016026B (zh) 2008-04-25 2014-07-02 东丽株式会社 含有来自丙型肝炎病毒的嵌合基因的核酸
BRPI0910482A2 (pt) 2008-04-29 2019-09-24 Abbott Lab imunoglobinas de domínio variável duplo e usos das mesmas
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
CN102076865B (zh) 2008-05-02 2016-03-16 西雅图基因公司 用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物
AR071698A1 (es) 2008-05-09 2010-07-07 Abbott Gmbh & Co Kg Anticuerpos contra el receptor de productos finales de glicosilacion avanzada (rage) y usos de los mismos
EP2599793A1 (en) 2008-05-29 2013-06-05 Nuclea Biotechnologies, Inc. Anti-phospho-akt antibodies
AU2009256246B2 (en) 2008-06-03 2013-07-18 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
EP2297209A4 (en) * 2008-06-03 2012-08-01 Abbott Lab IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
WO2010006059A1 (en) 2008-07-08 2010-01-14 Abbott Laboratories Prostaglandin e2 binding proteins and uses thereof
BRPI0915448A2 (pt) 2008-07-08 2015-11-10 Abbott Lab imunoglobulinas de domínio variável duplo para prostaglandina e2 e usos das mesmas
DK2982695T3 (da) 2008-07-09 2019-05-13 Biogen Ma Inc Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf
CN105085349B (zh) 2008-07-21 2018-02-09 布赖汉姆妇女医院 与合成的β‑1,6 葡糖胺寡糖相关的方法和组合物
WO2010017598A1 (en) 2008-08-14 2010-02-18 Arana Therapeutics Limited Anti-il-12/il-23 antibodies
MX2011001911A (es) 2008-08-18 2011-07-04 Pfizer Anticuerpos para ccr2.
US8663640B2 (en) * 2008-08-29 2014-03-04 Symphogen A/S Methods using recombinant anti-epidermal growth factor receptor antibody compositions
KR101442323B1 (ko) 2008-09-07 2014-09-25 글라이코넥스 인코포레이티드 항-연장된 ⅰ형 글라이코스핑고지질 항체, 이의 유도체 및 용도
CN110317272A (zh) 2008-10-14 2019-10-11 霍夫曼-拉罗奇有限公司 免疫球蛋白变体及其用途
EP2350270B1 (en) 2008-10-24 2018-03-07 The Government of the United States of America, as represented by the Secretary, Department of Health & Human Services Human ebola virus species and compositions and methods thereof
EP2356251A1 (en) 2008-11-07 2011-08-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Teneurin and cancer
EP2191842A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
EP2191843A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP2191841A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
BRPI0922807A2 (pt) * 2008-12-04 2015-12-22 Abbott Lab imonuglobulinas de domínio variável duplo e usos dos mesmos
MX348166B (es) 2008-12-19 2017-06-01 Macrogenics Inc Diacuerpos covalentes y sus usos.
WO2010078526A1 (en) 2008-12-31 2010-07-08 Biogen Idec Ma Inc. Anti-lymphotoxin antibodies
CA2749339A1 (en) 2009-01-12 2010-07-15 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
BRPI1007345A2 (pt) 2009-01-20 2019-04-16 H. ZADEH Homayoun regeneração óssea de anticorpo mediado
US8852608B2 (en) 2009-02-02 2014-10-07 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
US20110014190A1 (en) 2009-02-12 2011-01-20 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
CN102481341B (zh) 2009-02-23 2017-05-17 希托马克斯医疗有限公司 蛋白原及其使用方法
PE20160651A1 (es) 2009-03-05 2016-07-24 Abbvie Inc Proteinas de union a il-17
EP2405920A1 (en) 2009-03-06 2012-01-18 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Novel therapy for anxiety
CA2755640C (en) 2009-03-20 2018-05-22 Genentech, Inc. Bispecific antibody with a single antigen-binding domain specific for both her3 and egfr
JP2012521216A (ja) 2009-03-24 2012-09-13 テバ バイオファーマスーティカルズ ユーエスエー，インコーポレーテッド Ｌｉｇｈｔに対するヒト化抗体およびその使用
CA2787099A1 (en) 2009-03-30 2010-10-14 Anice C. Lowen Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof
EP2241323A1 (en) 2009-04-14 2010-10-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tenascin-W and brain cancers
CA2758964A1 (en) 2009-04-16 2010-10-21 Abbott Biotherapeutics Corp. Anti-tnf-.alpha. antibodies and their uses
NZ596837A (en) 2009-06-17 2014-02-28 Abbvie Biotherapeutics Inc Anti-vegf antibodies and their uses
JP5918129B2 (ja) 2009-06-22 2016-05-18 メディミューン，エルエルシー 部位特異的共役のための操作されたＦｃ領域
US20120288495A1 (en) 2009-07-22 2012-11-15 Biothera, Inc. Therapeutic compositions and methods
US9217157B2 (en) 2009-07-27 2015-12-22 Icahn School Of Medicine At Mount Sinai Recombinant influenza viruses and uses thereof
UY32808A (es) * 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
US8828406B2 (en) 2009-07-30 2014-09-09 Icahn School Of Medicine At Mount Sinai Influenza viruses and uses thereof
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
JP5762408B2 (ja) 2009-08-13 2015-08-12 クルセル ホランド ベー ヴェー ヒト呼吸器合胞体ウイルス（ｒｓｖ）に対する抗体および使用方法
CN102741288B (zh) 2009-08-29 2015-08-19 Abbvie公司 治疗用dll4结合蛋白
JP2013503607A (ja) 2009-09-01 2013-02-04 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリンおよびその使用
ES2354922B1 (es) 2009-09-02 2012-02-07 Fundacion Institut De Recerca De L'hospital Universitari Vall D'hebron Marcadores para la selección de terapias personalizadas para el tratamiento del c�?ncer.
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
EP2480573A1 (en) 2009-09-22 2012-08-01 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating cancer by modulating mex-3
AR078470A1 (es) 2009-10-02 2011-11-09 Sanofi Aventis Anticuerpos que se unen especificamente al receptor epha2
CN102666874B (zh) 2009-10-07 2016-06-01 宏观基因有限公司 由于岩藻糖基化程度的改变而表现出改善的效应子功能的含Fc区的多肽及其使用方法
WO2011045352A2 (en) 2009-10-15 2011-04-21 Novartis Forschungsstiftung Spleen tyrosine kinase and brain cancers
MX2012004415A (es) 2009-10-15 2012-05-08 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EP2493929B1 (en) 2009-10-28 2017-08-16 AbbVie Biotherapeutics Inc. Anti-egfr antibodies and their uses
US20120220594A1 (en) 2009-10-30 2012-08-30 Bristol-Meyers Squibb Company Methods for treating cancer in patients having igf-1r inhibitor resistance
US20120213801A1 (en) 2009-10-30 2012-08-23 Ekaterina Gresko Phosphorylated Twist1 and cancer
WO2011053707A1 (en) 2009-10-31 2011-05-05 Abbott Laboratories Antibodies to receptor for advanced glycation end products (rage) and uses thereof
JP2013509874A (ja) 2009-11-04 2013-03-21 エラスムス ユニバーシティ メディカル センター ロッテルダム 新脈管形成を調節する為の新規化合物及びこれらの化合物を使用する処置方法
WO2011060246A2 (en) 2009-11-12 2011-05-19 Genentech, Inc. A method of promoting dendritic spine density
PL2719708T3 (pl) 2009-11-13 2018-04-30 Daiichi Sankyo Europe Gmbh Materiał i sposoby leczenia lub zapobiegania chorobom związanym z HER-3
CN107337734A (zh) 2009-12-04 2017-11-10 弗·哈夫曼-拉罗切有限公司 多特异性抗体、抗体类似物、组合物和方法
EP2510001B1 (en) 2009-12-08 2015-12-02 AbbVie Deutschland GmbH & Co KG Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
EP2513148B1 (en) 2009-12-16 2016-08-31 AbbVie Biotherapeutics Inc. Anti-her2 antibodies and their uses
US8461328B2 (en) 2010-01-12 2013-06-11 Genentech, Inc. Tricyclic heterocyclic compounds, compositions and methods of use thereof
WO2011097527A2 (en) 2010-02-04 2011-08-11 Xencor, Inc. Immunoprotection of therapeutic moieties using enhanced fc regions
US20110189178A1 (en) * 2010-02-04 2011-08-04 Xencor, Inc. Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
CN102933231B (zh) 2010-02-10 2015-07-29 伊缪诺金公司 Cd20抗体及其用途
BR112012017405A2 (pt) 2010-02-18 2018-08-14 Genentech Inc método para aumentar o tempo até a recorrência do tumor em paciente com câncer
KR101853278B1 (ko) 2010-03-02 2018-05-02 애브비 인코포레이티드 치료학적 ｄｌｌ４ 결합 단백질
EP2542692B1 (en) 2010-03-04 2016-08-24 Carpén, Olli Method for selecting patients for treatment with an egfr inhibitor
EP2542578A1 (en) 2010-03-05 2013-01-09 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Smoc1, tenascin-c and brain cancers
JP2013522267A (ja) 2010-03-17 2013-06-13 エフ．ホフマン−ラ ロシュ アーゲー イミダゾピリジン化合物、組成物、および使用法
AU2011235569B2 (en) 2010-03-29 2016-06-30 Zymeworks Bc Inc. Antibodies with enhanced or suppressed effector function
EP3248615A1 (en) 2010-03-30 2017-11-29 Mount Sinai School of Medicine of New York University Influenza virus vaccines and uses thereof
EP2371369A1 (en) 2010-04-01 2011-10-05 Institut Gustave Roussy (IGR) EGFR inhibitor and antiviral agent for simultaneous, separate or sequential use in the treatment and/or prevention and/or palliation of cancer
EP4450523A3 (en) 2010-04-02 2025-03-12 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
EP3670534A3 (en) * 2010-04-15 2020-09-09 Amgen Inc. Human fgf receptor and beta-klotho binding proteins
CN102933601B (zh) 2010-04-15 2016-06-08 Abbvie公司 β淀粉样蛋白结合蛋白
BR112012026470A2 (pt) 2010-04-16 2016-08-09 Genentech Inc método para prever a sensibilidade de crescimento de células tumorais e para tratar um tumor em um paciente
WO2011131611A1 (en) 2010-04-19 2011-10-27 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Modulating xrn1
UY33386A (es) 2010-05-14 2011-12-30 Abbott Laboratoires Proteínas de unión a il-1
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
WO2011156617A2 (en) 2010-06-09 2011-12-15 Aveo Pharmaceuticals, Inc. Anti-egfr antibodies
US20130089538A1 (en) 2010-06-10 2013-04-11 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute forBiomedical Researh Treating cancer by modulating mammalian sterile 20-like kinase 3
EP3459558B1 (en) 2010-06-25 2020-07-29 Aston University Glycoproteins having lipid mobilizing properties and therapeutic uses thereof
US20120009196A1 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
CN103097412B (zh) 2010-07-09 2016-08-10 克鲁塞尔荷兰公司 抗人呼吸道合胞病毒(rsv)抗体以及使用方法
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US8637641B2 (en) 2010-07-29 2014-01-28 Xencor, Inc. Antibodies with modified isoelectric points
SG187682A1 (en) 2010-08-02 2013-03-28 Macrogenics Inc Covalent diabodies and uses thereof
JP2013537415A (ja) 2010-08-03 2013-10-03 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
EP2601287B1 (en) 2010-08-05 2015-01-07 Amgen Inc. Dipeptides to enhance yield and viability from cell cultures
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
US9505829B2 (en) 2010-08-19 2016-11-29 Zoetis Belgium S.A. Anti-NGF antibodies and their use
US9464136B2 (en) 2010-08-20 2016-10-11 Massachusetts Institute Of Technology Antibody-based constructs directed against tyrosine kinase receptors
CN103260639A (zh) 2010-08-26 2013-08-21 Abbvie公司 双重可变结构域免疫球蛋白及其用途
DK2612151T3 (en) 2010-08-31 2017-10-02 Genentech Inc BIOMARKETS AND METHODS OF TREATMENT
US20130171159A1 (en) 2010-09-10 2013-07-04 Brian Arthur Hemmings Phosphorylated twist1 and metastasis
KR20130051507A (ko) 2010-09-15 2013-05-20 에프. 호프만-라 로슈 아게 아자벤조티아졸 화합물, 조성물 및 사용 방법
MX2013003681A (es) 2010-10-01 2013-11-20 Moderna Therapeutics Inc Ácidos nucleicos manipulados y métodos de uso de los mismos.
WO2012054748A2 (en) 2010-10-22 2012-04-26 Seattle Genetics, Inc. Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway
MX2013004761A (es) 2010-10-29 2013-08-27 Immunogen Inc Nuevas moleculas de union al receptor del factor de crecimiento epidermico (egfr) e inmunoconjugados de estas.
EA201390575A1 (ru) 2010-10-29 2014-01-30 Иммьюноджен, Инк. Неантагонистические egfr-связывающие молекулы и их иммуноконъюгаты
WO2012065161A2 (en) 2010-11-12 2012-05-18 Scott & White Healthcare Antibodies to tumor endothelial marker 8
US20140093506A1 (en) 2010-11-15 2014-04-03 Marc Buehler Anti-fungal-agents
EP2640384A1 (en) 2010-11-18 2013-09-25 Synta Pharmaceuticals Corp. Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status
CN103313987A (zh) 2010-11-19 2013-09-18 弗·哈夫曼-拉罗切有限公司 吡唑并吡啶化合物、吡唑并吡啶化合物以及它们作为tyk2抑制剂的用途
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
WO2012121775A2 (en) 2010-12-21 2012-09-13 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
WO2012088094A2 (en) 2010-12-21 2012-06-28 Abbott Laboratories Il-1 binding proteins
WO2012085176A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
PL2668209T3 (pl) 2011-01-24 2021-11-02 Gilead Sciences, Inc. Przeciwciało selektywne dla komórek z wysoką gęstością egfr
WO2012103165A2 (en) 2011-01-26 2012-08-02 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
AR085911A1 (es) 2011-03-16 2013-11-06 Sanofi Sa Dosis terapeutica segura de una proteina similar a un anticuerpo con region v dual
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
CN103619881B (zh) * 2011-04-07 2017-07-28 安姆根有限公司 新的egfr结合蛋白
EP3403672A1 (en) 2011-04-20 2018-11-21 Medlmmune, LLC Antibodies and other molecules that bind b7-h1 and pd-1
JP6038884B2 (ja) 2011-04-20 2016-12-07 アムゲン・インコーポレーテッド 自動式注射装置
US9133493B2 (en) 2011-04-21 2015-09-15 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
GB201106870D0 (en) 2011-04-26 2011-06-01 Univ Belfast Marker
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
MX347818B (es) 2011-05-21 2017-05-15 Macrogenics Inc Dominios que enlazan suero desinmunizados y su uso para prolongar la vida media en suero.
WO2012162561A2 (en) 2011-05-24 2012-11-29 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
WO2012168259A1 (en) 2011-06-06 2012-12-13 Novartis Forschungsstiftung, Zweigniederlassung Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
LT2718320T (lt) 2011-06-10 2018-04-10 Medimmune Limited Anti-pseodomonas psl surišančios molekulės ir jų panaudojimas
US20140120555A1 (en) 2011-06-20 2014-05-01 Pierre Fabre Medicament Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
JP2014527397A (ja) 2011-06-20 2014-10-16 トラスラショナル、キャンサー、ドラッグス、ファーマ、ソシエダッド、リミターダＴｒａｓｌａｔｉｏｎａｌ Ｃａｎｃｅｒ Ｄｒｕｇｓ Ｐｈａｒｍａ， Ｓ．Ｌ． 癌患者の化学療法に対する臨床応答を予測する方法
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
LT2726600T (lt) 2011-07-01 2017-05-25 Amgen Inc. Žinduolių ląstelių kultūra
WO2019071023A1 (en) 2017-10-04 2019-04-11 Yale University COMPOSITIONS AND METHODS FOR MAKING POLYPEPTIDES CONTAINING SELENOCYSTEINE
US9464288B2 (en) 2011-07-11 2016-10-11 Yale University Compositions and methods for making selenocysteine containing polypeptides
HK1198328A1 (zh) 2011-07-13 2015-04-02 Abbvie Inc. 使用抗il-13抗體治療哮喘的方法和組合物
WO2013007768A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
WO2013007765A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
WO2013022855A1 (en) 2011-08-05 2013-02-14 Xencor, Inc. Antibodies with modified isoelectric points and immunofiltering
CN103889976A (zh) 2011-08-12 2014-06-25 弗·哈夫曼-拉罗切有限公司 吲唑化合物、组合物及使用方法
EP2756094B1 (en) 2011-08-15 2017-12-27 Medlmmune, LLC Anti-b7-h4 antibodies and their uses
KR20140057326A (ko) 2011-08-17 2014-05-12 제넨테크, 인크. 뉴레귤린 항체 및 그의 용도
WO2013033008A2 (en) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
CN103917458A (zh) 2011-09-02 2014-07-09 安姆根有限公司 药物产品和分析药物产品的光暴露的方法
EP2753356B1 (en) 2011-09-09 2021-12-22 Medimmune Limited Anti-siglec-15 antibodies and uses thereof
MX351251B (es) 2011-09-09 2017-10-06 Amgen Inc Uso del estado del virus del papiloma humano en establecer el uso de un agente que enlaza el receptor del factor de crecimiento anti-epidermal en el tratamiento de cáncer.
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
HK1198365A1 (en) 2011-09-20 2015-04-10 F. Hoffmann-La Roche Ag Imidazopyridine compounds, compositions and methods of use
CN108164602A (zh) 2011-09-20 2018-06-15 西奈山医学院 流感病毒疫苗及其应用
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
WO2013055809A1 (en) 2011-10-10 2013-04-18 Xencor, Inc. A method for purifying antibodies
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
EP2766497A1 (en) 2011-10-13 2014-08-20 Bristol-Myers Squibb Company Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
US8999331B2 (en) 2011-10-24 2015-04-07 Abbvie Inc. Immunobinders directed against sclerostin
UY34409A (es) 2011-10-24 2013-05-31 Abbvie Inc Inmunoenlazadores dirigidos contra el tnf
US9272002B2 (en) 2011-10-28 2016-03-01 The Trustees Of The University Of Pennsylvania Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
EP2773664A1 (en) 2011-11-01 2014-09-10 Bionomics, Inc. Anti-gpr49 antibodies
ES2697674T3 (es) 2011-11-01 2019-01-25 Bionomics Inc Procedimientos para bloquear el crecimiento de células madre cancerosas
AU2012332587B2 (en) 2011-11-01 2017-02-23 Bionomics, Inc. Antibodies and methods of treating cancer
AU2012332593B2 (en) 2011-11-01 2016-11-17 Bionomics, Inc. Anti-GPR49 antibodies
ES2861435T3 (es) 2011-11-03 2021-10-06 Univ Pennsylvania Composiciones específicas de B7-H4 aisladas y métodos de uso de las mismas
WO2013070468A1 (en) 2011-11-08 2013-05-16 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
EP2776565A1 (en) 2011-11-08 2014-09-17 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the nervous system
WO2013068431A1 (en) 2011-11-08 2013-05-16 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research New treatment for neurodegenerative diseases
EP2776838A1 (en) 2011-11-08 2014-09-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Early diagnostic of neurodegenerative diseases
AU2012335247A1 (en) 2011-11-08 2014-05-29 Pfizer Inc. Methods of treating inflammatory disorders using anti-M-CSF antibodies
WO2013075048A1 (en) 2011-11-16 2013-05-23 Amgen Inc. Methods of treating epidermal growth factor deletion mutant viii related disorders
MX2014006087A (es) 2011-11-21 2014-08-01 Immunogen Inc Metodo de tratamiento de tumores que son resistentes a terapias contra el receptor del factor de crecimiento epidermico (egfr) con agentes citotoxicos conjugados con anticuerpos dirigidos contra el receptor del factor de crecimiento epidermico.
AU2012346540C1 (en) 2011-11-30 2019-07-04 Genentech, Inc. ErbB3 mutations in cancer
RU2632108C2 (ru) 2011-12-08 2017-10-02 Биотест Аг Применения иммуноконъюгатов, мишенью которых является cd138
CN104136462B (zh) 2011-12-14 2017-06-09 艾伯维德国有限责任两合公司 用于诊断和治疗铁相关病症的组合物和方法
AU2012352168C1 (en) 2011-12-14 2018-01-25 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
AR089231A1 (es) 2011-12-15 2014-08-06 Amgen Inc Metodo de floculacion
SMT202200355T1 (it) 2011-12-16 2022-11-18 Modernatx Inc Composizioni di mrna modificato
CN103172741B (zh) * 2011-12-20 2018-04-27 智翔（上海）医药科技有限公司 全人源抗egfr抗体
CA3111357A1 (en) 2011-12-23 2013-06-27 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
UY34558A (es) 2011-12-30 2013-07-31 Abbvie Inc Proteínas de unión específicas duales dirigidas contra il-13 y/o il-17
WO2013102825A1 (en) 2012-01-02 2013-07-11 Novartis Ag Cdcp1 and breast cancer
CN104471064B (zh) 2012-01-20 2018-11-02 中华人民共和国香港特别行政区政府 副粘病毒及其用途
EP3369746A1 (en) 2012-01-27 2018-09-05 AbbVie Deutschland GmbH & Co KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
KR102102111B1 (ko) * 2012-02-08 2020-04-20 아이쥐엠 바이오사이언스 인코포레이티드 Ｃｄｉｍ 결합 단백질 및 이의 용도
CN104254778A (zh) 2012-02-10 2014-12-31 西雅图遗传学公司 Cd30+癌症的检测和治疗
WO2013120553A1 (en) 2012-02-15 2013-08-22 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1)
WO2013120554A1 (en) 2012-02-15 2013-08-22 Novo Nordisk A/S Antibodies that bind peptidoglycan recognition protein 1
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
JP2015514710A (ja) 2012-03-27 2015-05-21 ジェネンテック， インコーポレイテッド Ｈｅｒ３阻害剤に関する診断及び治療
WO2013144240A1 (en) 2012-03-29 2013-10-03 Friedrich Miescher Institute For Biomedical Research Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
EP2834260A4 (en) 2012-04-02 2016-08-10 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF MEMBRANE PROTEINS
WO2013151649A1 (en) 2012-04-04 2013-10-10 Sialix Inc Glycan-interacting compounds
EP2836514A4 (en) 2012-04-13 2015-12-30 Childrens Medical Center TIKI INHIBITORS
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013166043A1 (en) 2012-05-02 2013-11-07 Children's Hospital Medical Center Rejuvenation of precursor cells
WO2013166290A1 (en) 2012-05-04 2013-11-07 Abbvie Biotherapeutics Inc. P21 biomarker assay
EA030716B1 (ru) 2012-05-14 2018-09-28 Байоджен Ма Инк. Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны
WO2013172951A1 (en) 2012-05-15 2013-11-21 Morphotek, Inc. Methods for treatment of gastric cancer
US9944707B2 (en) 2012-05-17 2018-04-17 Sorrento Therapeutics, Inc. Antibodies that bind epidermal growth factor receptor (EGFR)
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US10233503B2 (en) 2012-05-24 2019-03-19 Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) Method for the identification of the origin of a cancer of unknown primary origin by methylation analysis
WO2013177386A1 (en) 2012-05-24 2013-11-28 Abbvie Biotherapeutics Inc. Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
ES2894852T3 (es) 2012-06-06 2022-02-16 Zoetis Services Llc Anticuerpos anti-NGF caninizados y métodos de los mismos
HUE043552T2 (hu) 2012-06-08 2019-09-30 Sutro Biopharma Inc Antitestek, amelyek tartalmaznak helyspecifikus nem természetes aminosav maradékokat, eljárások elõállításukra és eljárások használatukra
US20150218238A1 (en) 2012-06-29 2015-08-06 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear Treating diseases by modulating a specific isoform of mkl1
US20150184154A1 (en) 2012-07-05 2015-07-02 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear New treatment for neurodegenerative diseases
US20150224190A1 (en) 2012-07-06 2015-08-13 Mohamed Bentires-Alj Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the IL-8/CXCR interaction
AR091755A1 (es) 2012-07-12 2015-02-25 Abbvie Inc Proteinas de union a il-1
JP2015524255A (ja) 2012-07-13 2015-08-24 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 二重特異性抗体を共導入することによってｃａｒｔ細胞の活性を強化する方法
PL2882440T3 (pl) 2012-08-07 2019-07-31 Novartis Ag Kombinacje farmaceutyczne zawierające inhibitor b-raf, inhibitor egfr i opcjonalnie inhibitor pi3k-alfa
EP2890402B1 (en) 2012-08-31 2019-04-17 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
WO2014035475A1 (en) 2012-09-02 2014-03-06 Abbvie Inc. Methods to control protein heterogeneity
AR092745A1 (es) 2012-10-01 2015-04-29 Univ Pennsylvania Composiciones que comprenden un dominio de union anti-fap y metodos para hacer blanco en celulas estromales para el tratamiento del cancer
NO2760138T3 (cg-RX-API-DMAC7.html) 2012-10-01 2018-08-04
WO2014055771A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
AU2013328580B2 (en) 2012-10-12 2016-01-21 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
AU2013334493B2 (en) 2012-10-26 2018-11-29 The University Of Queensland Use of endocytosis inhibitors and antibodies for cancer therapy
CN105431453A (zh) 2012-11-01 2016-03-23 艾伯维公司 稳定的双重可变结构域免疫球蛋白制剂
KR20210111353A (ko) 2012-11-01 2021-09-10 애브비 인코포레이티드 항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
EP2922554B1 (en) 2012-11-26 2022-02-23 ModernaTX, Inc. Terminally modified rna
US20140154255A1 (en) 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
UA118255C2 (uk) 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
CN108641002A (zh) 2012-12-18 2018-10-12 西奈山伊坎医学院 流感病毒疫苗及其用途
WO2014100439A2 (en) 2012-12-19 2014-06-26 Amplimmune, Inc. B7-h4 specific antibodies, and compositions and methods of use thereof
MX2015008117A (es) 2012-12-21 2016-03-31 Amplimmune Inc Anticuerpos anti-h7cr.
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
CA3211863A1 (en) 2013-01-14 2014-07-17 Xencor, Inc. Novel heterodimeric proteins
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
WO2014109858A1 (en) 2013-01-14 2014-07-17 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
WO2014113510A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
EP2951199A4 (en) 2013-01-31 2016-07-20 Univ Jefferson Fusion proteins for the modulation of regulatory and effector T cells
WO2014129895A1 (en) 2013-02-19 2014-08-28 Stichting Vu-Vumc Means and method for increasing the sensitivity of cancers for radiotherapy
WO2014128235A1 (en) 2013-02-22 2014-08-28 F. Hoffmann-La Roche Ag Methods of treating cancer and preventing drug resistance
KR20150143458A (ko) 2013-03-06 2015-12-23 메리맥 파마슈티컬즈, 인크. 항-C-MET 탠덤 Fc 이중특이적 항체
CN105246511A (zh) 2013-03-06 2016-01-13 豪夫迈·罗氏有限公司 治疗和预防癌症药物抗性的方法
CA2905010A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
PT2968555T (pt) 2013-03-13 2020-07-14 Univ California Composições compreendendo anticorpos anti-cd38 e carfilzomib
MX2015011898A (es) 2013-03-13 2016-05-05 Genentech Inc Compuestos de pirazolo y usos de los mismos.
CN105209077B (zh) 2013-03-13 2019-06-11 麦迪穆有限责任公司 吡咯并苯并二氮杂卓以及其结合物
CN105228649B (zh) 2013-03-14 2019-01-18 雅培制药有限公司 Hcv抗原-抗体组合测定和方法以及用在其中的组合物
MX2015012922A (es) 2013-03-14 2016-04-04 Ren Liu Tratamiento del cancer usando anticuerpos que se unen a grp78 en la superficie celular.
JP6739329B2 (ja) 2013-03-14 2020-08-12 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ Ｈｃｖコア脂質結合ドメインモノクローナル抗体
US9994908B2 (en) 2013-03-14 2018-06-12 Abbott Molecular Inc. Materials and methods for assessment of colorectal adenoma
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
WO2014143342A1 (en) 2013-03-14 2014-09-18 Abbott Laboratories Hcv ns3 recombinant antigens and mutants thereof for improved antibody detection
BR112015022604A2 (pt) 2013-03-14 2017-10-24 Genentech Inc usos de um modulador de modificador de cromatina e um antagonista de egfr
US20140271634A1 (en) 2013-03-14 2014-09-18 The Regents Of The University Of California Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
TWI625390B (zh) 2013-03-14 2018-06-01 安美基公司 用於增加重組蛋白質之甘露糖含量之方法
PL3395423T3 (pl) 2013-03-14 2024-03-18 Amgen Inc. Usuwanie wypłukanych ligandów do oczyszczania na zasadzie powinowactwa
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
WO2014144096A1 (en) 2013-03-15 2014-09-18 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
MX2015011899A (es) 2013-03-15 2016-05-05 Genentech Inc Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
CA2903495C (en) 2013-03-15 2021-05-25 Amgen Inc. Body contour adaptable autoinjector device
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
US10544187B2 (en) 2013-03-15 2020-01-28 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US9469686B2 (en) 2013-03-15 2016-10-18 Abbott Laboratories Anti-GP73 monoclonal antibodies and methods of obtaining the same
HK1220214A1 (zh) 2013-03-15 2017-04-28 Abbvie Biotherapeutics Inc. Fc变体
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
EP2968545B1 (en) 2013-03-15 2019-03-06 Memorial Sloan Kettering Cancer Center High affinity anti-gd2 antibodies
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
WO2014145000A2 (en) 2013-03-15 2014-09-18 Abbvie Biotherapeutics Inc. Anti-cd25 antibodies and their uses
EP2970489A2 (en) 2013-03-15 2016-01-20 AbbVie Biotechnology Ltd Anti-cd25 antibodies and their uses
EA201890895A1 (ru) 2013-03-15 2019-02-28 Зинджения, Инк. Мультивалентные и моновалентные мультиспецифические комплексы и их применение
TWI639449B (zh) 2013-03-15 2018-11-01 美商安美基公司 用於注射器之匣盒
AU2014227732A1 (en) 2013-03-15 2015-09-17 Abbvie Inc. Dual specific binding proteins directed against IL-1 beta and IL-17
EP2985292A4 (en) * 2013-04-07 2016-12-21 Genrix(Shanghai) Biopharmacertical Co Ltd ANTIBODY OF THE RECEPTOR OF THE EPIDERMAL GROWTH FACTOR
JP6433085B2 (ja) 2013-04-09 2018-12-05 ボストン バイオメディカル， インコーポレイテッド がんの処置に使用するための２−アセチルナフト［２，３−ｂ］フラン−４，９−ジオン
KR102539359B1 (ko) 2013-04-19 2023-06-02 싸이튠 파마 감소된 혈관 누출 증후군에 대한 사이토카인 유도체 치료
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
EP2981822B1 (en) 2013-05-06 2020-09-02 Scholar Rock, Inc. Compositions and methods for growth factor modulation
CN103290018B (zh) * 2013-05-07 2015-07-29 南方医科大学 一种与人表皮生长因子受体iii型突变体特异性结合的核酸适配子及其应用
KR20160129698A (ko) 2013-05-24 2016-11-09 메디뮨 엘엘씨 항-b7-h5 항체 및 이의 용도
US9481901B2 (en) 2013-05-30 2016-11-01 Amgen Inc. Methods for increasing mannose content of recombinant proteins
CA2914369C (en) 2013-06-06 2023-02-14 Igenica Biotherapeutics, Inc. Anti-c10orf54 antibodies and uses thereof
JP6581572B2 (ja) 2013-06-07 2019-09-25 デューク ユニバーシティ 補体因子ｈ阻害薬
CA2914924A1 (en) 2013-06-13 2014-12-18 Fast Forward Pharmaceuticals B.V. Cd40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an tgr5-receptor agonist, an fxr agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis.
US9499628B2 (en) 2013-06-14 2016-11-22 Children's Hospital Medical Center Method of boosting the immune response in neonates
EP3016980B1 (en) 2013-07-05 2020-05-06 Formation Biologics Inc. Egfr antibody conjugates
ES2658039T3 (es) 2013-07-10 2018-03-08 Sutro Biopharma, Inc. Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
WO2015019286A1 (en) 2013-08-07 2015-02-12 Friedrich Miescher Institute For Biomedical Research New screening method for the treatment friedreich's ataxia
WO2015035044A2 (en) 2013-09-04 2015-03-12 Abbvie Biotherapeutics Inc. Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
AU2014318017B2 (en) 2013-09-05 2020-02-06 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
US9505767B2 (en) 2013-09-05 2016-11-29 Genentech, Inc. Pyrazolo[1,5-A]pyrimidin-7(4H)-onehistone demethylase inhibitors
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
EA201600252A1 (ru) 2013-09-12 2017-05-31 Галозим, Инк. Модифицированные антитела к рецепторам антиэпидермального фактора роста и способы их использования
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
TW201605857A (zh) 2013-10-03 2016-02-16 赫孚孟拉羅股份公司 Ｃｄｋ８之醫療性抑制劑及其用途
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
EP3055298B1 (en) 2013-10-11 2020-04-29 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
CA2925598A1 (en) 2013-10-18 2015-04-23 Genentech, Inc. Anti-rspo antibodies and methods of use
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015066027A2 (en) 2013-10-28 2015-05-07 Dots Devices, Inc. Allergen detection
MX373301B (es) 2013-10-31 2020-04-24 Sanofi Sa Anticuerpos anti-cd38 específicos para usarse para tratar cánceres humanos.
CA2929077C (en) 2013-10-31 2024-05-28 Amgen Inc. Use of monensin to regulate glycosylation of recombinant proteins
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US20160367662A1 (en) 2013-12-12 2016-12-22 Novartis Ag Combinations of trametinib, panitumumab and dabrafenib for the treatment of cancer
US9944694B2 (en) 2013-12-13 2018-04-17 Rijksuniversiteit Groningen Antibodies against Staphylococcus aureus and uses therof
CN105934253A (zh) 2013-12-17 2016-09-07 豪夫迈·罗氏有限公司 使用pd-1轴结合拮抗剂和抗her2抗体治疗her2阳性癌症的方法
JP2017501167A (ja) 2013-12-17 2017-01-12 ジェネンテック， インコーポレイテッド Ｏｘ４０結合アゴニスト及びｐｄ−１軸結合アンタゴニストを含む併用療法
US10273301B2 (en) 2013-12-24 2019-04-30 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
EP2893939A1 (en) 2014-01-10 2015-07-15 Netris Pharma Anti-netrin-1 antibody
CN112481337B (zh) 2014-01-13 2024-06-25 美国安进公司 调控鸟氨酸代谢以操控重组蛋白的高甘露糖糖型含量
US10106829B2 (en) 2014-01-29 2018-10-23 Amgen Inc. Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
AU2014380174C1 (en) 2014-01-29 2025-06-05 Amgen Inc. Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
MX2016012285A (es) 2014-03-24 2017-01-23 Genentech Inc Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
BR112016022385A2 (pt) 2014-03-28 2018-06-19 Xencor, Inc anticorpos específicos que se ligam a cd38 e cd3
JP6637439B2 (ja) 2014-03-31 2020-01-29 ジェネンテック， インコーポレイテッド 抗ｏｘ４０抗体及び使用方法
EP3126386A1 (en) 2014-03-31 2017-02-08 F. Hoffmann-La Roche AG Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
WO2015153916A1 (en) 2014-04-04 2015-10-08 Bionomics, Inc. Humanized antibodies that bind lgr5
EP3148567A4 (en) 2014-04-25 2018-01-10 The Brigham and Women's Hospital, Inc. Methods to manipulate alpha-fetoprotein (afp)
AU2015259053B2 (en) 2014-05-16 2020-12-24 Amgen Inc. Assay for detecting Th1 and Th2 cell populations
JP6832709B2 (ja) 2014-05-16 2021-02-24 メディミューン，エルエルシー 新生児Ｆｃ受容体結合が改変されて治療および診断特性が強化された分子
RS61678B1 (sr) 2014-05-28 2021-05-31 Agenus Inc Anti-gitr antitela i postupci za njihovu primenu
LT3926051T (lt) 2014-06-04 2024-06-10 Amgen Inc. Žinduolių ląstelių kultūros surinkimo metodai
JP5924795B2 (ja) 2014-06-13 2016-05-25 テンボロン オイ 複合体
US20170137824A1 (en) 2014-06-13 2017-05-18 Indranil BANERJEE New treatment against influenza virus
WO2015198202A1 (en) 2014-06-23 2015-12-30 Friedrich Miescher Institute For Biomedical Research Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas
EP3164129A1 (en) 2014-07-01 2017-05-10 Friedrich Miescher Institute for Biomedical Research Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
CN113214397A (zh) 2014-07-17 2021-08-06 诺和诺德股份有限公司 定点诱变trem-1抗体以降低黏度
US10851149B2 (en) 2014-08-14 2020-12-01 The Trustees Of The University Of Pennsylvania Treatment of cancer using GFR α-4 chimeric antigen receptor
CA2958882A1 (en) 2014-09-02 2016-03-10 Immunogen, Inc. Methods for formulating antibody drug conjugate compositions
CN107074823B (zh) 2014-09-05 2021-05-04 基因泰克公司 治疗性化合物及其用途
EP3193940A1 (en) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
JP2017529358A (ja) 2014-09-19 2017-10-05 ジェネンテック， インコーポレイテッド がんの処置のためのｃｂｐ／ｅｐ３００阻害剤およびｂｅｔ阻害剤の使用
WO2016046768A1 (en) 2014-09-24 2016-03-31 Friedrich Miescher Institute For Biomedical Research Lats and breast cancer
EP3200804A4 (en) 2014-10-01 2018-04-18 Eagle Biologics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
JP6783230B2 (ja) 2014-10-10 2020-11-11 ジェネンテック， インコーポレイテッド ヒストンデメチラーゼのインヒビターとしてのピロリドンアミド化合物
WO2016059600A1 (en) 2014-10-17 2016-04-21 Novartis Ag Combination of ceritinib with an egfr inhibitor
SG10202006685XA (en) 2014-10-23 2020-08-28 Innate Pharma Treatment of Cancers Using Anti-NKG2A Agents
CN107106609A (zh) 2014-10-31 2017-08-29 宾夕法尼亚大学董事会 刺激和扩展t细胞的组合物和方法
EP4653013A2 (en) 2014-10-31 2025-11-26 The Trustees of the University of Pennsylvania Methods and compositions for modified t cells
CN107206024B (zh) 2014-10-31 2021-12-03 宾夕法尼亚大学董事会 改变cart细胞中的基因表达及其用途
SG11201703446RA (en) 2014-10-31 2017-05-30 Abbvie Biotherapeutics Inc Anti-cs1 antibodies and antibody drug conjugates
CN107109484B (zh) 2014-11-03 2021-12-14 豪夫迈·罗氏有限公司 用于ox40激动剂治疗的功效预测和评估的方法和生物标志物
WO2016073378A1 (en) 2014-11-03 2016-05-12 Genentech, Inc. Assays for detecting t cell immune subsets and methods of use thereof
CN107073126A (zh) 2014-11-06 2017-08-18 豪夫迈·罗氏有限公司 包含ox40结合激动剂和tigit抑制剂的组合疗法
JP6639497B2 (ja) 2014-11-10 2020-02-05 ジェネンテック， インコーポレイテッド ブロモドメインインヒビターおよびその使用
MA40940A (fr) 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA40943A (fr) 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
EP3218005B1 (en) 2014-11-12 2023-01-04 Seagen Inc. Glycan-interacting compounds and methods of use
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
SG10201807625PA (en) 2014-11-17 2018-10-30 Genentech Inc Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
HK1244037B (en) 2014-11-19 2019-11-15 Amgen Inc. Quantitation of glycan moiety in recombinant glycoproteins
WO2016086189A2 (en) 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies that bind cd3 and tumor antigens
SG11201704274QA (en) 2014-11-26 2017-06-29 Xencor Inc Heterodimeric antibodies that bind cd3 and cd38
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
EP3632915A1 (en) 2014-11-27 2020-04-08 Genentech, Inc. 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
EP3680344A1 (en) 2014-12-01 2020-07-15 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein
RU2020123953A (ru) 2014-12-09 2020-09-18 Эббви Инк. Ингибирующие bcl-xl соединения, обладающие низкой клеточной проницаемостью, и конъюгаты антитело-лекарственное средство, включающие их
WO2016091891A1 (en) 2014-12-09 2016-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies against axl
BR112017012377A2 (pt) 2014-12-09 2018-04-24 Abbvie Inc conjugados anticorpo-fármaco com inibidores de bcl-xl permeáveis à célula
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
KR102693806B1 (ko) 2014-12-11 2024-08-09 피에르 파브르 메디카먼트 항-c10orf54 항체들 및 그들의 용도들
JP6827928B2 (ja) 2014-12-19 2021-02-10 ユニヴェルシテ・ドゥ・ナント 抗ｉｌ−３４抗体
ES2862701T3 (es) 2014-12-22 2021-10-07 Univ Rockefeller Anticuerpos agonistas anti-MERTK y usos de los mismos
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
AU2015369624A1 (en) 2014-12-23 2017-06-08 Genentech, Inc. Compositions and methods for treating and diagnosing chemotherapy-resistant cancers
WO2016109546A2 (en) 2014-12-30 2016-07-07 Genentech, Inc. Methods and compositions for prognosis and treatment of cancers
US10435467B2 (en) 2015-01-08 2019-10-08 Biogen Ma Inc. LINGO-1 antagonists and uses for treatment of demyelinating disorders
CN107406429B (zh) 2015-01-09 2021-07-06 基因泰克公司 哒嗪酮衍生物及其在治疗癌症中的用途
WO2016112284A1 (en) 2015-01-09 2016-07-14 Genentech, Inc. (piperidin-3-yl)(naphthalen-2-yl)methanone derivatives and related compounds as inhibitors of the histone demethylase kdm2b for the treatment of cancer
JP6889661B2 (ja) 2015-01-09 2021-06-18 ジェネンテック， インコーポレイテッド ４，５−ジヒドロイミダゾール誘導体およびヒストンジメチラーゼ（ｋｄｍ２ｂ）インヒビターとしてのその使用
SG10201906471PA (en) 2015-01-14 2019-09-27 Brigham & Womens Hospital Inc Treatment of cancer with anti-lap monoclonal antibodies
CA2974699A1 (en) 2015-01-23 2016-07-28 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
CN107531692B (zh) 2015-01-29 2020-12-25 基因泰克公司 治疗化合物及其用途
JP6636031B2 (ja) 2015-01-30 2020-01-29 ジェネンテック， インコーポレイテッド 治療用化合物およびその使用
ES2947589T3 (es) 2015-01-31 2023-08-11 Univ Pennsylvania Composiciones y métodos para el suministro de moléculas terapéuticas a linfocitos T
MA41598A (fr) 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
LT3265123T (lt) 2015-03-03 2023-01-25 Kymab Limited Antikūnai, naudojimas ir būdai
WO2016141387A1 (en) 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
AU2016231327B2 (en) 2015-03-06 2018-08-09 CSL Behring Lengnau AG Modified von Willebrand factor having improved half-life
WO2016149368A1 (en) 2015-03-17 2016-09-22 Memorial Sloan Kettering Cancer Center Anti-muc16 antibodies and uses thereof
HK1249532A1 (zh) 2015-04-07 2018-11-02 F. Hoffmann-La Roche Ag 具有激动剂活性的抗原结合复合体及使用方法
MY189692A (en) 2015-05-07 2022-02-26 Memorial Sloan Kettering Cancer Center Anti-ox40 antibodies and methods of use thereof
ES2835866T5 (es) 2015-05-12 2024-12-02 Hoffmann La Roche Procedimientos terapéuticos y de diagnóstico para el cáncer
EP3447075B1 (en) 2015-05-15 2023-08-09 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
RS60792B1 (sr) 2015-05-29 2020-10-30 Agenus Inc Anti-ctla-4 antitela i postupci za njihovu primenu
EP3303632B2 (en) 2015-05-29 2023-05-10 F. Hoffmann-La Roche AG Therapeutic and diagnostic methods for cancer
HUE048284T2 (hu) 2015-05-29 2020-07-28 Abbvie Inc Anti-CD40 antitestek és alkalmazásuk
BR112017026025A2 (pt) 2015-06-03 2018-08-14 Boston Biomedical Inc composições que compreendem um inibidor de stemness de câncer e um agente imunoterápico para uso no tratamento de câncer
AU2016274585A1 (en) 2015-06-08 2017-12-14 Genentech, Inc. Methods of treating cancer using anti-OX40 antibodies
US20170000885A1 (en) 2015-06-08 2017-01-05 Genentech, Inc. Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
KR102689256B1 (ko) 2015-06-17 2024-07-30 제넨테크, 인크. Pd-1 축 결합 길항제 및 탁산을 사용하여 국소적 진행성 또는 전이성 유방암을 치료하는 방법
CN114805576A (zh) 2015-06-24 2022-07-29 詹森药业有限公司 抗vista抗体和片段
PL3341376T3 (pl) 2015-08-26 2021-08-02 Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Skondensowane związki tricykliczne jako inhibitory kinaz białkowych
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
AU2016317915B2 (en) 2015-09-01 2021-02-18 Agenus Inc. Anti-PD-1 antibodies and methods of use thereof
SMT202500003T1 (it) 2015-09-25 2025-03-12 Hoffmann La Roche Anticorpi anti-tigit e procedimenti di utilizzo
EP3368566A1 (en) 2015-10-28 2018-09-05 Friedrich Miescher Institute for Biomedical Research Tenascin-w and biliary tract cancers
TW201720459A (zh) 2015-11-02 2017-06-16 妮翠斯製藥公司 Ntn1中和劑與抑制後生控制之藥物之組合治療
JP2019500011A (ja) 2015-11-03 2019-01-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 腫瘍選択性及び阻害性が増強された二重特異性抗体及びその使用
JP7066613B2 (ja) 2015-11-12 2022-05-13 シージェン インコーポレイテッド グリカン相互作用化合物および使用方法
PT3380525T (pt) 2015-11-25 2024-02-05 Immunogen Inc Formulações farmacêuticas e métodos que as utilizam
CA3006610A1 (en) 2015-11-30 2017-06-08 Abbvie Inc. Anti-hulrrc15 antibody drug conjugates and methods for their use
AU2016365114A1 (en) 2015-11-30 2018-05-17 Abbvie Biotherapeutics Inc. Anti-huLRRC15 antibody drug conjugates and methods for their use
AU2016365318B2 (en) 2015-12-02 2024-04-18 Board Of Regents, The University Of Texas System Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
WO2017096017A1 (en) 2015-12-02 2017-06-08 Stsciences, Inc. Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
CA3007030A1 (en) 2015-12-07 2017-06-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
SG11201804204QA (en) 2015-12-16 2018-06-28 Genentech Inc Process for the preparation of tricyclic pi3k inhibitor compounds and methods for using the same for the treatment of cancer
EP3184544A1 (en) 2015-12-23 2017-06-28 Julius-Maximilians-Universität Würzburg Glycoprotein v inhibitors for use as coagulants
SG11201805605TA (en) 2015-12-31 2018-07-30 Progastrine Et Cancers S A R L Compositions and methods for detecting and treating ovarian cancer
KR102477179B1 (ko) 2015-12-31 2022-12-13 프로가스트린 에 캔서스 에스.에이 알.엘. 위암의 검출 및 치료를 위한 조성물 및 방법
CA3009785A1 (en) 2015-12-31 2017-07-06 Progastrine Et Cancers S.A R.L. Compositions and methods for detecting and treating esophageal cancer
EP3397965B1 (en) 2015-12-31 2024-09-11 ECS-Progastrin SA Compositions and methods for assessing the risk of cancer occurrence
PL3400246T3 (pl) 2016-01-08 2021-03-08 F. Hoffmann-La Roche Ag Sposoby leczenia nowotworów z dodatnim markerem cea z wykorzystaniem antagonistów wiążących oś pd-1 oraz przeciwciał dwuswoistych anty-cea/anty-cd3
MX2018009800A (es) 2016-02-12 2018-11-09 Janssen Pharmaceutica Nv Anticuerpos y fragmentos anti-vista, usos de los mismos y procedimientos de identificacion de los mismos.
CN109196121B (zh) 2016-02-29 2022-01-04 基因泰克公司 用于癌症的治疗和诊断方法
EA201892063A1 (ru) 2016-03-14 2019-04-30 Юниверситетет И Осло МОДИФИЦИРОВАННЫЕ ИММУНОГЛОБУЛИНЫ С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ FcRn
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
SMT202000706T1 (it) 2016-03-17 2021-01-05 Tillotts Pharma Ag Anticorpi anti-tnf alfa e frammenti funzionali di essi
HUE052869T2 (hu) 2016-03-17 2021-05-28 Tillotts Pharma Ag TNF-ellenes alfa-antitestek és ezek funkcionális fragmentjei
IL261261B2 (en) 2016-03-17 2024-04-01 Numab Therapeutics AG Antibodies against TNF-ALPHA and their functional fragments
CN109153718B (zh) 2016-03-17 2022-02-08 努玛治疗有限公司 抗TNFα抗体及其功能片段
EP3430042B1 (en) 2016-03-17 2023-05-24 Numab Innovation AG Anti-tnfalpha-antibodies and functional fragments thereof
EP3432925A4 (en) 2016-03-22 2019-11-06 Bionomics Limited ADMINISTRATION OF A MONOCLONAL ANTI-LGR5 ANTIBODY
WO2017165683A1 (en) 2016-03-23 2017-09-28 Novartis Ag Cell secreted minibodies and uses thereof
KR20240034883A (ko) 2016-03-29 2024-03-14 얀센 바이오테크 인코포레이티드 항-il12 및/또는 항-il23 항체의 증가된 투여 간격을 사용한 건선의 치료
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
US20170319688A1 (en) 2016-04-14 2017-11-09 Genentech, Inc. Anti-rspo3 antibodies and methods of use
EP3443120A2 (en) 2016-04-15 2019-02-20 H. Hoffnabb-La Roche Ag Methods for monitoring and treating cancer
JP7503887B2 (ja) 2016-04-15 2024-06-21 ジェネンテック， インコーポレイテッド がんを監視及び治療するための方法
EP3443114A1 (en) 2016-04-15 2019-02-20 H. Hoffnabb-La Roche Ag Diagnostic and therapeutic methods for cancer
EP3454863A1 (en) 2016-05-10 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
TW201808336A (zh) 2016-05-11 2018-03-16 賽諾菲公司 用抗ｍｕｃ１類美登素免疫綴合物抗體治療腫瘤的治療方案
US20170348429A1 (en) 2016-05-17 2017-12-07 Abbvie Biotherapeutics Inc. ANTI-cMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
EP3464286B1 (en) 2016-05-24 2021-08-18 Genentech, Inc. Pyrazolopyridine derivatives for the treatment of cancer
JP7160688B2 (ja) 2016-05-24 2022-10-25 ジェネンテック， インコーポレイテッド Ｃｂｐ／ｅｐ３００の複素環式インヒビターおよびがんの処置におけるそれらの使用
WO2017205465A2 (en) 2016-05-24 2017-11-30 Griswold Karl Edwin Antibodies and methods of making same
NZ749355A (en) 2016-05-27 2023-04-28 Agenus Inc Anti-tim-3 antibodies and methods of use thereof
US10875921B2 (en) 2016-05-27 2020-12-29 Abbvie Biotherapeutics Inc. Anti-4-1BB antibodies and their uses
RU2752049C2 (ru) 2016-05-27 2021-07-22 Эббви Байотерапьютикс Инк. Антитела к cd40 и пути их применения
EP3462853B1 (en) 2016-06-03 2023-03-01 Regeneron Pharmaceuticals, Inc. Rodents expressing exogenous terminal deoxynucleotidyltransferase
CN109963870B (zh) 2016-06-08 2023-07-28 艾伯维公司 抗b7-h3抗体和抗体药物偶联物
US20200129519A1 (en) 2016-06-08 2020-04-30 Genentech, Inc. Diagnostic and therapeutic methods for cancer
WO2017215590A1 (en) 2016-06-13 2017-12-21 I-Mab Anti-pd-l1 antibodies and uses thereof
CA3026151A1 (en) 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
US11098107B2 (en) 2016-06-15 2021-08-24 Sutro Biopharma, Inc. Antibodies with engineered CH2 domains, compositions thereof and methods of using the same
MX2018015755A (es) 2016-06-15 2019-08-29 Icahn School Med Mount Sinai Proteinas de hemaglutinina de virus de influenza y usos de las mismas.
KR20190020341A (ko) 2016-06-28 2019-02-28 젠코어 인코포레이티드 소마토스타틴 수용체 2에 결합하는 이종이량체 항체
CA3030099A1 (en) 2016-07-08 2018-01-11 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
WO2018017964A2 (en) 2016-07-21 2018-01-25 Emory University Ebola virus antibodies and binding agents derived therefrom
CN109963871A (zh) 2016-08-05 2019-07-02 豪夫迈·罗氏有限公司 具有激动活性的多价及多表位抗体以及使用方法
WO2018029124A1 (en) 2016-08-08 2018-02-15 F. Hoffmann-La Roche Ag Therapeutic and diagnostic methods for cancer
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
MX2019002946A (es) 2016-09-14 2019-09-26 Abbvie Biotherapeutics Inc Anticuerpos anti-pd-1 y sus usos.
CN109219616B (zh) 2016-09-19 2022-10-21 天境生物科技(杭州)有限公司 Gm-csf抗体及其用途
EP4360714A3 (en) 2016-09-21 2024-07-24 Nextcure, Inc. Antibodies for siglec-15 and methods of use thereof
JP7069177B2 (ja) 2016-09-21 2022-05-17 ネクストキュア インコーポレイテッド シグレック－１５に対する抗体及びその使用方法
US20180094052A1 (en) 2016-09-30 2018-04-05 Janssen Biotech, Inc. Safe and Effective Method of Treating Psoriasis with Anti-IL23 Specific Antibody
ES3001985T3 (en) 2016-10-03 2025-03-06 Abbott Lab Improved methods of assessing uch-l1 in patient samples
KR102804118B1 (ko) 2016-10-06 2025-05-09 제넨테크, 인크. 암에 대한 치료 및 진단 방법
US20200023072A1 (en) 2016-10-11 2020-01-23 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
TWI843168B (zh) 2016-10-11 2024-05-21 美商艾吉納斯公司 抗ｌａｇ－３抗體及其使用方法
PE20240950A1 (es) 2016-10-14 2024-05-06 Xencor Inc PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa)
WO2018078143A1 (en) 2016-10-28 2018-05-03 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Means and methods for determining efficacy of anti-egfr inhibitors in colorectal cancer (crc) therapy
WO2018081648A2 (en) 2016-10-29 2018-05-03 Genentech, Inc. Anti-mic antibidies and methods of use
WO2018085359A1 (en) 2016-11-02 2018-05-11 Immunogen, Inc. Combination treatment with antibody-drug conjugates and parp inhibitors
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
JP7045724B2 (ja) 2016-11-07 2022-04-01 ニューラクル サイエンス カンパニー リミテッド 配列類似性を持つ抗ファミリー１９、メンバーａ５抗体及びその用途
CA3044244A1 (en) 2016-11-16 2018-05-24 Janssen Biotech, Inc. Method of treating psoriasis with anti-il23 specific antibody
EP3541847A4 (en) 2016-11-17 2020-07-08 Seattle Genetics, Inc. COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
WO2018102427A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
EP3551225A1 (en) 2016-12-07 2019-10-16 Agenus Inc. Antibodies and methods of use thereof
MD3551660T2 (ro) 2016-12-07 2024-03-31 Agenus Inc Anticorpi anti-CTLA-4 și procedee de utilizare a acestora
HUE050399T2 (hu) 2016-12-15 2020-12-28 Abbvie Biotherapeutics Inc Anti-OX40 antitestek és alkalmazásuk
US12162932B2 (en) 2017-01-05 2024-12-10 Netris Pharma Combined treatment with Netrin-1 interfering drug and immune checkpoint inhibitors drugs
TWI771361B (zh) 2017-01-20 2022-07-21 大陸商大有華夏生物醫藥集團有限公司 人程序性死亡受體pd-1的單株抗體及其片段
WO2018137598A1 (en) 2017-01-24 2018-08-02 I-Mab Anti-cd73 antibodies and uses thereof
EP3574012A1 (en) 2017-01-27 2019-12-04 Memorial Sloan Kettering Cancer Center Bispecific her2 and cd3 binding molecules
JP2020506916A (ja) 2017-01-30 2020-03-05 ヤンセン バイオテツク，インコーポレーテツド 活動性乾癬性関節炎の治療のための抗ｔｎｆ抗体、組成物、及び方法
CN110418652A (zh) 2017-02-07 2019-11-05 詹森生物科技公司 用于治疗活动性强直性脊柱炎的抗tnf抗体、组合物和方法
ES2953595T3 (es) 2017-03-01 2023-11-14 Hoffmann La Roche Procedimientos diagnósticos y terapéuticos para el cáncer
AU2018226824A1 (en) 2017-03-03 2019-09-19 Seagen Inc. Glycan-interacting compounds and methods of use
WO2018170099A1 (en) 2017-03-14 2018-09-20 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
TWI808963B (zh) 2017-03-22 2023-07-21 法商賽諾菲公司 使用人類化抗ｃｘｃｒ５抗體治療狼瘡
US11016092B2 (en) 2017-03-23 2021-05-25 Abbott Laboratories Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase L1
BR112019020224A2 (pt) 2017-03-30 2020-05-12 Progastrine Et Cancers S.À R.L. Composições e métodos para o tratamento do câncer de pulmão
BR112019020414A2 (pt) 2017-03-30 2020-06-09 Progastrine Et Cancers S A R L composições e métodos para detectar e tratar câncer de próstata usando moléculas de ligação à progastrina
EP3606555A4 (en) 2017-04-07 2021-08-04 Icahn School of Medicine at Mount Sinai INFLUENZA B VIRUS NEURAMINIDASE ANTIBODIES AND USES THEREOF
WO2018189220A1 (en) 2017-04-13 2018-10-18 F. Hoffmann-La Roche Ag An interleukin-2 immunoconjugate, a cd40 agonist, and optionally a pd-1 axis binding antagonist for use in methods of treating cancer
JP7297672B2 (ja) 2017-04-13 2023-06-26 アジェナス インコーポレイテッド 抗ｃｄ１３７抗体およびその使用方法
BR112019021612A2 (pt) 2017-04-15 2020-05-12 Abbott Laboratories Métodos para auxiliar o diagnóstico hiperagudo e determinação de traumatismo crânioencefálico em um indivíduo humano com o uso de biomarcadores precoces
WO2018193427A1 (en) 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
WO2018196782A1 (en) 2017-04-27 2018-11-01 The University Of Hong Kong Use of hcn inhibitors for treatment of cancer
EP3635407B1 (en) 2017-04-28 2025-09-10 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
SMT202300243T1 (it) 2017-05-01 2023-11-13 Agenus Inc Anticorpi anti-tigit e relativi metodi d'uso
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
CA3063324A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
CA3062656A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
US10866251B2 (en) 2017-05-25 2020-12-15 Abbott Laboratories Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
CN110709704B (zh) 2017-05-30 2024-06-21 雅培实验室 利用心肌肌钙蛋白i辅助诊断和评估人类受试者的轻度创伤性脑损伤的方法
CN111148762A (zh) 2017-05-31 2020-05-12 斯特库伯株式会社 免疫特异性结合至btn1a1的抗体和分子及其治疗性用途
CN111051346A (zh) 2017-05-31 2020-04-21 斯特库伯株式会社 使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法
KR20200026209A (ko) 2017-06-06 2020-03-10 주식회사 에스티큐브앤컴퍼니 Btn1a1 또는 btn1a1-리간드에 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법
AU2018291082B2 (en) 2017-06-27 2025-05-29 Neuracle Science Co., Ltd. Anti-FAM19A5 antibodies and uses thereof
AU2018291497A1 (en) 2017-06-30 2020-01-16 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
CU20200002A7 (es) 2017-07-14 2020-11-30 Pfizer Anticuerpos contra madcam
KR20240006698A (ko) 2017-07-21 2024-01-15 제넨테크, 인크. 암에 대한 치료 및 진단 방법
JP2020528936A (ja) 2017-07-27 2020-10-01 ノモキャン ファーマシューティカルズ エルエルシー Ｍ（ｈ）ｄｍ２／４に対する抗体、ならびにがんの診断および処置におけるそれらの使用
WO2020159504A1 (en) 2019-01-30 2020-08-06 Nomocan Pharmaceuticals Llc Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer
IL272183B1 (en) 2017-08-11 2025-10-01 Genentech Inc Anti-CD8 antibodies and their uses
US11021540B2 (en) 2017-09-07 2021-06-01 Augusta University Research Institute, Inc. Antibodies to programmed cell death protein 1
TW202428305A (zh) 2017-09-08 2024-07-16 美商建南德克公司 癌症之診斷及治療方法
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
CN111868039A (zh) 2017-09-26 2020-10-30 加利福尼亚大学董事会 用于治疗癌症的组合物和方法
CA3019207A1 (en) 2017-09-28 2019-03-28 The Governing Council Of The University Of Toronto Methods and compositions for inhibiting mutant egfr signaling
EP3694552A1 (en) 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
US11369608B2 (en) 2017-10-27 2022-06-28 University Of Virginia Patent Foundation Compounds and methods for regulating, limiting, or inhibiting AVIL expression
US20190160089A1 (en) 2017-10-31 2019-05-30 Immunogen, Inc. Combination treatment with antibody-drug conjugates and cytarabine
CN111315772A (zh) 2017-10-31 2020-06-19 斯塔顿生物技术有限公司 抗apoc3抗体及其使用方法
CA3081343A1 (en) 2017-11-06 2019-05-09 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
JP7544597B2 (ja) 2017-11-06 2024-09-03 ジェネンテック， インコーポレイテッド がんの診断及び療法
US11312770B2 (en) 2017-11-08 2022-04-26 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
WO2019099322A1 (en) 2017-11-16 2019-05-23 Amgen Inc. Autoinjector with stall and end point detection
MX2020005473A (es) 2017-11-27 2020-08-27 Purdue Pharma Lp Anticuerpos humanizados que se dirigen al factor tisular humano.
KR102461238B1 (ko) 2017-12-05 2022-11-01 프로가스트린 에 캔서스 에스.에이 알.엘. 암을 치료하기 위한 항-프로가스트린 항체와 면역치료 사이의 병용 치료
US11016105B2 (en) 2017-12-09 2021-05-25 Abbott Laboratories Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of GFAP and UCH-L1
CA3067057A1 (en) 2017-12-09 2019-06-13 Abbott Laboratories Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)
WO2019125732A1 (en) 2017-12-19 2019-06-27 Xencor, Inc. Engineered il-2 fc fusion proteins
JP7236164B2 (ja) 2018-01-15 2023-03-09 エピアクシス セラピューティクス プロプライエタリー リミテッド 治療法に対する応答を予測する薬剤及び方法
TW201940881A (zh) 2018-01-26 2019-10-16 瑞士商Ｅｃｓ前胃泌激素公司 在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術
US12180285B2 (en) 2018-02-01 2024-12-31 Memorial Sloan Kettering Cancer Center Antibodies to galectin-3 and methods of use thereof
US20200399376A1 (en) 2018-02-26 2020-12-24 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
CN112368579B (zh) 2018-02-27 2024-05-03 Ecs前胃泌素股份有限公司 作为生物标记物的前胃泌素用于免疫疗法
US20210002373A1 (en) 2018-03-01 2021-01-07 Nextcure, Inc. KLRG1 Binding Compositions and Methods of Use Thereof
CA3092551A1 (en) 2018-03-05 2019-09-12 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
EP3765499A1 (en) 2018-03-12 2021-01-20 Zoetis Services LLC Anti-ngf antibodies and methods thereof
EA202092286A1 (ru) 2018-03-26 2021-03-18 Эмджен Инк. Общие афукозилированные гликоформы антител, полученные в культуре клеток
EP3774902A1 (en) 2018-04-02 2021-02-17 Bristol-Myers Squibb Company Anti-trem-1 antibodies and uses thereof
WO2019195623A2 (en) 2018-04-04 2019-10-10 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
JP2021521273A (ja) 2018-04-12 2021-08-26 メディアファーマ エス．アール．エル． Ｌｇａｌｓ３ｂｐ抗体−薬剤結合体及びがん治療のためのその使用
CN112867734A (zh) 2018-04-18 2021-05-28 Xencor股份有限公司 包含IL-15/IL-15Ra Fc融合蛋白和PD-1抗原结合结构域的靶向PD-1的异源二聚体融合蛋白及其用途
US11505595B2 (en) 2018-04-18 2022-11-22 Xencor, Inc. TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
WO2019207159A1 (en) 2018-04-27 2019-10-31 Fondazione Ebri Rita Levi-Montalcini Antibody directed against a tau-derived neurotoxic peptide and uses thereof
IL321253A (en) 2018-05-01 2025-08-01 Amgen Inc Antibodies with a modulated glycan profile
CN119569873A (zh) 2018-05-10 2025-03-07 纽洛可科学有限公司 抗序列相似家族19成员a5的抗体及其使用方法
MA52590A (fr) 2018-05-11 2021-03-17 Janssen Biotech Inc Méthodes de traitement de la dépression à l'aide d'anticorps il-23
TW202003048A (zh) 2018-05-15 2020-01-16 美商伊繆諾金公司 用抗體-藥物偶聯物及flt3抑制劑之組合治療
CA3100200A1 (en) 2018-05-21 2019-11-28 Nanostring Technologies, Inc. Molecular gene signatures and methods of using same
CA3098103A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
US12364746B2 (en) 2018-06-21 2025-07-22 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
KR20210040945A (ko) 2018-06-21 2021-04-14 유마니티 테라퓨틱스, 인크. 신경장애의 치료 및 예방을 위한 조성물 및 방법
CA3103017A1 (en) 2018-06-23 2019-12-26 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
US11884729B2 (en) 2018-06-29 2024-01-30 ApitBio, Inc Anti-L1CAM antibodies and uses thereof
US10976561B2 (en) 2018-06-29 2021-04-13 Viavi Solutions Inc. Optical devices with azimuthal modulator layer
US20200025776A1 (en) 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained Response Predictors After Treatment With Anti-IL23 Specific Antibody
TW202011991A (zh) 2018-07-18 2020-04-01 美商建南德克公司 用pd-1軸結合拮抗劑、抗代謝劑及鉑劑治療肺癌之方法
JP7519985B2 (ja) 2018-07-19 2024-07-22 タユー ファシャ バイオテック メディカル グループ カンパニー， リミテッド 抗ｐｄ－１抗体、投薬量、およびその使用
MX2021000786A (es) 2018-07-20 2021-06-15 Pf Medicament Receptor para supresor de ig del dominio v de activación de células t (vista).
US20210186880A1 (en) 2018-08-03 2021-06-24 Brown University Oral formulations with increased uptake
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
TW202024023A (zh) 2018-09-03 2020-07-01 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
AU2019342099A1 (en) 2018-09-19 2021-04-08 Genentech, Inc. Therapeutic and diagnostic methods for bladder cancer
WO2020061349A1 (en) 2018-09-21 2020-03-26 Genentech, Inc. Diagnostic methods for triple-negative breast cancer
SI3883606T1 (sl) 2018-09-24 2023-10-30 Janssen Biotech, Inc. Varen in učinkovit postopek zdravljenja ulceroznega kolitisa s protitelesom proti IL12/IL23
EP3861016A2 (en) 2018-10-03 2021-08-11 Xencor, Inc. Il-12 heterodimeric fc-fusion proteins
EP3860713A2 (en) 2018-10-03 2021-08-11 Staten Biotechnology B.V. Antibodies specific for human and cynomolgus apoc3 and methods of use thereof
GB201816553D0 (en) 2018-10-10 2018-11-28 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
WO2020076969A2 (en) 2018-10-10 2020-04-16 Tilos Therapeutics, Inc. Anti-lap antibody variants and uses thereof
GB201816554D0 (en) 2018-10-10 2018-11-28 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
US12286487B2 (en) 2018-10-11 2025-04-29 University Of Florida Research Foundation, Incorporated Antibody compounds with reactive arginine and related antibody drug conjugates
US12404540B2 (en) 2018-10-17 2025-09-02 The University Of Queensland Epigenetic biomarker and uses therefor
AU2019361983A1 (en) 2018-10-18 2021-05-20 Genentech, Inc. Diagnostic and therapeutic methods for sarcomatoid kidney cancer
WO2020086328A1 (en) 2018-10-25 2020-04-30 The Medical College Of Wisconsin, Inc. Targeting clptm1l for treatment and prevention of cancer
US20220170097A1 (en) 2018-10-29 2022-06-02 The Broad Institute, Inc. Car t cell transcriptional atlas
IL282530B2 (en) 2018-10-31 2025-07-01 Intocell Inc History of compressed heterocyclic benzodiazepines and their uses
US11548941B2 (en) 2018-11-20 2023-01-10 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-IL-23 specific antibody
EP3883610A4 (en) 2018-11-20 2022-11-02 Cornell University MACROCYCLIC COMPLEXES OF RADIONUCLIDES AND THEIR USE IN CANCER RADIATION THERAPY
WO2020118011A1 (en) 2018-12-06 2020-06-11 Alexion Pharmaceuticals, Inc. Anti-alk2 antibodies and uses thereof
US12422441B2 (en) 2018-12-07 2025-09-23 Georgia Tech Research Corporation Antibodies that bind to natively folded myocilin
WO2020127374A2 (en) 2018-12-17 2020-06-25 Alligator Bioscience Ab Novel polypeptides
EP3898681A2 (en) 2018-12-17 2021-10-27 Alligator Bioscience AB Polypeptides
MA54562A (fr) 2018-12-18 2021-10-27 Janssen Biotech Inc Méthode sûre et efficace de traitement du lupus avec un anticorps anti-il12/il23
US12180207B2 (en) 2018-12-19 2024-12-31 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of FGFR tyrosine kinases
EP3898615A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
US20220025045A1 (en) 2018-12-26 2022-01-27 Innate Pharma Compounds and methods for treatment of head and neck cancer
TWI873112B (zh) 2018-12-28 2025-02-21 日商協和麒麟股份有限公司 與TfR結合之雙專一性抗體
SG11202104217QA (en) 2019-01-02 2021-05-28 Neuracle Science Co Ltd Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
WO2020148651A1 (en) 2019-01-15 2020-07-23 Janssen Biotech, Inc. Anti-tnf antibody compositions and methods for the treatment of juvenile idiopathic arthritis
MA54814A (fr) 2019-01-23 2021-12-01 Janssen Biotech Inc Compositions d'anticorps anti-tnf destinées à être utilisées dans des méthodes de traitement d'arthrite psoriasique
US12397014B2 (en) 2019-02-05 2025-08-26 The Brigham And Women's Hospital, Inc. Polysaccharide compositions for use in treating filariasis
EP3921443A1 (en) 2019-02-08 2021-12-15 F. Hoffmann-La Roche AG Diagnostic and therapeutic methods for cancer
EP3928790A4 (en) 2019-02-22 2023-01-11 Wuhan Yzy Biopharma Co., Ltd. Cd3 antigen binding fragment and application thereof
MX2021010003A (es) 2019-02-26 2021-12-10 Inspirna Inc Anticuerpos anti-mertk de alta afinidad y usos de los mismos.
US20220146495A1 (en) 2019-02-27 2022-05-12 Epiaxis Therapeutics Pty Ltd Methods and agents for assessing t-cell function and predicting response to therapy
WO2020176748A1 (en) 2019-02-27 2020-09-03 Genentech, Inc. Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies
AU2020232605A1 (en) 2019-03-01 2021-10-21 Xencor, Inc. Heterodimeric antibodies that bind ENPP3 and CD3
EA202192508A1 (ru) 2019-03-14 2022-03-29 Янссен Байотек, Инк. Способы получения композиций антитела к фно
JP7635137B2 (ja) 2019-03-14 2025-02-25 ヤンセン バイオテツク，インコーポレーテツド 抗ｔｎｆ抗体組成物を産生するための方法
KR20210142002A (ko) 2019-03-14 2021-11-23 얀센 바이오테크 인코포레이티드 항-tnf 항체 조성물을 생성하기 위한 제조 방법
WO2020183418A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Manufacturing methods for producing anti-il12/il23 antibody compositions
CN113631575A (zh) 2019-03-15 2021-11-09 笛卡尔疗法股份有限公司 抗bcma嵌合抗原受体
AU2020243588B2 (en) 2019-03-18 2025-12-18 Janssen Biotech, Inc. Method of treating psoriasis in pediatric subjects with anti-IL12/IL23 antibody
CN113661180B (zh) 2019-03-27 2025-08-26 宾夕法尼亚大学董事会 Tn-MUC1嵌合抗原受体(CAR)T细胞疗法
EP3947442A2 (en) 2019-03-28 2022-02-09 Danisco US Inc. Engineered antibodies
WO2020223233A1 (en) 2019-04-30 2020-11-05 Genentech, Inc. Prognostic and therapeutic methods for colorectal cancer
TWI879768B (zh) 2019-05-03 2025-04-11 美商建南德克公司 用抗pd-l1抗體治療癌症之方法
JP2022534020A (ja) 2019-05-23 2022-07-27 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
MX2021014882A (es) 2019-06-03 2022-03-25 Janssen Biotech Inc Anticuerpos anti-tnf, composiciones y métodos para el tratamiento de la espondilitis anquilosante activa.
JP2022536279A (ja) 2019-06-03 2022-08-15 ヤンセン バイオテツク，インコーポレーテツド 乾癬性関節炎を治療するための抗ｔｎｆ抗体組成物及び方法
EP3980065A4 (en) 2019-06-04 2023-07-05 Janssen Biotech, Inc. SAFE AND EFFECTIVE METHOD OF TREATMENT OF PSORIAL ARTHRITIS WITH ANTI-IL23 SPECIFIC ANTIBODY
JP7706210B2 (ja) 2019-06-10 2025-07-11 ストロ バイオファーマ インコーポレーテッド ５Ｈ－ピロロ［３，２－ｄ］ピリミジン－２，４－ジアミノ化合物およびその抗体コンジュゲート
US20220259202A1 (en) 2019-06-17 2022-08-18 Sutro Biopharma, Inc. 1-(4-(aminomethyl)benzyl)-2-butyl-2h-pyrazolo[3,4-c]quinolin-4-amine derivatives and related compounds as toll-like receptor (tlr) 7/8 agonists, as well as antibody drug conjugates thereof for use in cancer therapy and diagnosis
CN112300279A (zh) 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 针对抗cd73抗体和变体的方法和组合物
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
WO2021034616A1 (en) 2019-08-16 2021-02-25 Children' S Hospital Medical Center Methods of treating a subject with a cdc42-specific inhibitor
AU2020335928A1 (en) 2019-08-30 2022-02-17 Agenus Inc. Anti-CD96 antibodies and methods of use thereof
WO2021043206A1 (zh) 2019-09-03 2021-03-11 百奥泰生物制药股份有限公司 一种抗tigit免疫抑制剂及应用
CN114616250B (zh) 2019-09-04 2024-11-08 豪夫迈·罗氏有限公司 Cd8结合剂及其用途
WO2021062372A1 (en) 2019-09-26 2021-04-01 Amgen Inc. Methods of producing antibody compositions
CN114729045B (zh) 2019-09-26 2025-09-09 斯特库比公司 对糖基化的ctla-4特异性的抗体及其使用方法
EP4048693A1 (en) 2019-09-27 2022-08-31 F. Hoffmann-La Roche AG Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
EP4041768A1 (en) 2019-10-09 2022-08-17 StCube & Co. Antibodies specific to glycosylated lag3 and methods of use thereof
JP2023511472A (ja) 2019-10-29 2023-03-20 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がんの治療のための二官能性化合物
US11802151B2 (en) 2019-11-04 2023-10-31 Code Biotherapeutics, Inc. Brain-specific angiogenesis inhibitor 1 (BAI1) antibodies and uses thereof
WO2021092171A1 (en) 2019-11-06 2021-05-14 Genentech, Inc. Diagnostic and therapeutic methods for treatment of hematologic cancers
AU2020381458A1 (en) 2019-11-13 2022-05-12 Genentech, Inc. Therapeutic compounds and methods of use
EP3825330A1 (en) 2019-11-19 2021-05-26 International-Drug-Development-Biotech Anti-cd117 antibodies and methods of use thereof
US11897950B2 (en) 2019-12-06 2024-02-13 Augusta University Research Institute, Inc. Osteopontin monoclonal antibodies
WO2021118924A2 (en) 2019-12-12 2021-06-17 Ting Therapeutics Llc Compositions and methods for the prevention and treatment of hearing loss
AU2020403145B2 (en) 2019-12-13 2025-06-26 Genentech, Inc. Anti-Ly6G6D antibodies and methods of use
TW202136276A (zh) 2019-12-20 2021-10-01 美商艾瑞斯卡公司 三環吡啶酮及嘧啶酮
CN115052663A (zh) 2020-01-08 2022-09-13 辛瑟斯治疗股份有限公司 Alk5抑制剂缀合物及其用途
US20230047549A1 (en) 2020-01-15 2023-02-16 WuXi Biologics Ireland Limited An apparatus and a method for continuously harvesting a biological substance produced by a cultured cell
WO2021194481A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
US20230095053A1 (en) 2020-03-03 2023-03-30 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
WO2021178896A1 (en) 2020-03-06 2021-09-10 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
WO2021177980A1 (en) 2020-03-06 2021-09-10 Genentech, Inc. Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
JPWO2021177438A1 (cg-RX-API-DMAC7.html) * 2020-03-06 2021-09-10
EP4118112A1 (en) 2020-03-10 2023-01-18 Massachusetts Institute of Technology Compositions and methods for immunotherapy of npm1c-positive cancer
WO2021202473A2 (en) 2020-03-30 2021-10-07 Danisco Us Inc Engineered antibodies
US20240228592A1 (en) 2020-03-31 2024-07-11 Bio-Thera Solutions, Ltd. Antibody and fusion protein for treating coronaviruses and use thereof
WO2021202959A1 (en) 2020-04-03 2021-10-07 Genentech, Inc. Therapeutic and diagnostic methods for cancer
EP4132971A1 (en) 2020-04-09 2023-02-15 Merck Sharp & Dohme LLC Affinity matured anti-lap antibodies and uses thereof
EP4136459A1 (en) 2020-04-13 2023-02-22 Abbott Laboratories Methods, complexes and kits for detecting or determining an amount of a ss-coronavirus antibody in a sample
EP4143234A4 (en) 2020-04-26 2024-07-17 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Modified immunoglobulins
EP4143345A1 (en) 2020-04-28 2023-03-08 Genentech, Inc. Methods and compositions for non-small cell lung cancer immunotherapy
BR112022022378A2 (pt) 2020-05-05 2022-12-13 Janssen Biotech Inc Métodos para tratamento da doença de crohn com anticorpo específico anti-il23
EP4149548A4 (en) 2020-05-13 2024-05-08 Disc Medicine, Inc. ANTI-HEMOJUVELIN ANTIBODIES (HJV) FOR THE TREATMENT OF MYELOFIBROSIS
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
KR20230023663A (ko) 2020-05-21 2023-02-17 얀센 바이오테크 인코포레이티드 Il-23 및 tnf 알파에 대한 항체의 병용 요법으로 염증성 장질환을 치료하는 방법
EP3915641A1 (en) 2020-05-27 2021-12-01 International-Drug-Development-Biotech Anti-cd5 antibodies and methods of use thereof
EP3915576A1 (en) 2020-05-28 2021-12-01 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Chimeric antigen receptors specific for p95her2 and uses thereof
EP4161653A1 (en) 2020-06-03 2023-04-12 Bionecure Therapeutics, Inc. Trophoblast cell-surface antigen-2 (trop-2) antibodies
US20230273126A1 (en) 2020-06-04 2023-08-31 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
WO2021257503A1 (en) 2020-06-16 2021-12-23 Genentech, Inc. Methods and compositions for treating triple-negative breast cancer
JP2023531200A (ja) 2020-06-18 2023-07-21 ジェネンテック， インコーポレイテッド 抗ｔｉｇｉｔ抗体及びｐｄ－１軸結合アンタゴニストを用いた治療
EP4172621A1 (en) 2020-06-30 2023-05-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies
JP7741831B2 (ja) 2020-06-30 2025-09-18 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 術前補助療法及び根治手術後の固形がんを患っている患者の再発及び／又は死亡のリスクを予測するための方法
AU2021308574A1 (en) 2020-07-13 2023-03-09 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-IL23 specific antibody
EP3939999A1 (en) 2020-07-14 2022-01-19 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Interleukin 11 receptor alpha subunit (il11ra) neutralizing antibodies and uses thereof
US11787775B2 (en) 2020-07-24 2023-10-17 Genentech, Inc. Therapeutic compounds and methods of use
EP4185322A2 (en) 2020-07-24 2023-05-31 Amgen Inc. Immunogens derived from sars-cov2 spike protein
CA3190230A1 (en) 2020-07-30 2022-02-03 Janssen Biotech, Inc. Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody
WO2022031749A1 (en) 2020-08-03 2022-02-10 Genentech, Inc. Diagnostic and therapeutic methods for lymphoma
EP4193149A1 (en) 2020-08-04 2023-06-14 Abbott Laboratories Improved methods and kits for detecting sars-cov-2 protein in a sample
CN114057877A (zh) 2020-08-07 2022-02-18 百奥泰生物制药股份有限公司 抗pd-l1抗体及其应用
WO2022036146A1 (en) 2020-08-12 2022-02-17 Genentech, Inc. Diagnostic and therapeutic methods for cancer
EP4210832A1 (en) 2020-09-14 2023-07-19 Vor Biopharma, Inc. Chimeric antigen receptors for treatment of cancer
WO2022066805A1 (en) 2020-09-23 2022-03-31 Erasca, Inc. Tricyclic pyridones and pyrimidones
CN116406291A (zh) 2020-10-05 2023-07-07 基因泰克公司 用抗fcrh5/抗cd3双特异性抗体进行治疗的给药
AU2021360897A1 (en) 2020-10-15 2023-05-25 Amgen Inc. Relative unpaired glycans in antibody production methods
WO2022079211A1 (en) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugates
EP4242232A4 (en) 2020-11-06 2024-09-11 Bio-Thera Solutions, Ltd. BISPECIFIC ANTIBODY AND ITS USE
WO2022103983A2 (en) 2020-11-11 2022-05-19 Sutro Biopharma, Inc. Fluorenylmethyloxycarbonyl and fluorenylmethylaminocarbonyl compounds, protein conjugates thereof, and methods for their use
EP4253415A4 (en) 2020-11-12 2024-10-02 Mabwell (Shanghai) Bioscience Co., Ltd. Antibody and preparation method therefor
AU2021381419A1 (en) * 2020-11-20 2023-06-29 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Modified egfr antibody with reduced affinity, drug conjugate, and use thereof
WO2022104697A1 (en) * 2020-11-20 2022-05-27 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Modified egfr antibody with reduced affinity
WO2023102384A1 (en) 2021-11-30 2023-06-08 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
CA3198161A1 (en) 2020-12-01 2022-06-09 Beth MCQUISTON Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
US20230107642A1 (en) 2020-12-18 2023-04-06 Erasca, Inc. Tricyclic pyridones and pyrimidones
EP4271998A1 (en) 2020-12-30 2023-11-08 Abbott Laboratories Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
CN116745324A (zh) 2021-01-27 2023-09-12 信达生物制药(苏州)有限公司 针对cd16a的单域抗体及其用途
TW202241454A (zh) 2021-02-01 2022-11-01 日商第一三共股份有限公司 抗體－免疫賦活化劑共軛物之新穎製造方法
CA3210553A1 (en) 2021-02-12 2022-08-18 F. Hoffmann-La Roche Ag Bicyclic tetrahydroazepine derivatives for the treatment of cancer
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
WO2022187591A1 (en) 2021-03-05 2022-09-09 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
CA3212665A1 (en) 2021-03-09 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
WO2022192586A1 (en) 2021-03-10 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3
IL305816A (en) 2021-03-12 2023-11-01 Daiichi Sankyo Co Ltd Glycan and a method for preparing a medicine containing it
KR20230156387A (ko) 2021-03-12 2023-11-14 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체에 의해 건선성 관절염을 치료하는 안전하고 효과적인 방법
US20220289834A1 (en) 2021-03-12 2022-09-15 Janssen Biotech, Inc. Method of Treating Psoriatic Arthritis Patients with Inadequate Response to TNF Therapy with Anti-IL23 Specific Antibody
US20240376224A1 (en) 2021-04-02 2024-11-14 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
EP4334353A1 (en) 2021-05-04 2024-03-13 Regeneron Pharmaceuticals, Inc. Multispecific fgf21 receptor agonists and their uses
BR112023024169A2 (pt) 2021-05-18 2024-02-06 Abbott Lab Métodos para avaliar lesão cerebral em um indivíduo pediátrico
TW202313633A (zh) 2021-05-25 2023-04-01 美商伊瑞斯卡公司 含硫雜芳族三環ｋｒａｓ抑制劑
CA3222409A1 (en) 2021-06-07 2022-12-15 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
IL309349A (en) 2021-06-14 2024-02-01 argenx BV Antibodies against interleukin 9 and methods of using them
CA3222291A1 (en) 2021-06-14 2022-12-22 Jaime MARINO Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
WO2022266206A1 (en) 2021-06-16 2022-12-22 Erasca, Inc. Kras inhibitor conjugates
KR20240032991A (ko) 2021-07-09 2024-03-12 얀센 바이오테크 인코포레이티드 항-tnf 항체 조성물의 생성을 위한 제조 방법
EP4367136A1 (en) 2021-07-09 2024-05-15 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
EP4367138A1 (en) 2021-07-09 2024-05-15 Janssen Biotech, Inc. Manufacturing methods for producing anti-il12/il23 antibody compositions
WO2023010060A2 (en) 2021-07-27 2023-02-02 Novab, Inc. Engineered vlrb antibodies with immune effector functions
US20240352481A1 (en) 2021-07-29 2024-10-24 Vor Biopharma Inc. Nfat-responsive reporter systems for assessing chimeric antigen receptor activation and methods of making and using the same
US20250101126A1 (en) 2021-08-05 2025-03-27 Go Therapeutics, Inc. Anti-glyco-muc4 antibodies and their uses
EP4384522A1 (en) 2021-08-10 2024-06-19 Erasca, Inc. Selective kras inhibitors
IL310862A (en) 2021-08-16 2024-04-01 Hemogenyx Pharmaceuticals Llc Anti-flt3 antibodies, cars, car t cells and methods of use
JP2024532173A (ja) 2021-08-17 2024-09-05 ヒーモジェニックス ファーマシューティカルズ エルエルシー 二重特異性抗ｆｌｔ３／ｃｄ３抗体及び使用方法
AU2022339759A1 (en) 2021-08-31 2024-03-07 Abbott Laboratories Methods and systems of diagnosing brain injury
US12467921B2 (en) 2021-08-31 2025-11-11 Versitech Limited Antibodies and assays for detection of Burkholderia mallei
CN118715440A (zh) 2021-08-31 2024-09-27 雅培实验室 诊断脑损伤的方法和系统
WO2023034571A1 (en) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-lamp1 antibodies and their uses
AU2022339667A1 (en) 2021-09-03 2024-04-11 Go Therapeutics, Inc. Anti-glyco-cmet antibodies and their uses
AU2022354059A1 (en) 2021-09-30 2024-03-28 Abbott Laboratories Methods and systems of diagnosing brain injury
JP2024534661A (ja) 2021-09-30 2024-09-20 バイオ－テラ ソリュ－ションズ，エルティーディー． 抗ｂ７－ｈ３抗体及びその応用
EP4413377A1 (en) 2021-10-05 2024-08-14 Amgen Inc. Fc-gamma receptor ii binding and glycan content
AU2022374890A1 (en) 2021-10-29 2024-06-13 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
AU2021362997A1 (en) 2021-11-03 2024-05-16 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
WO2023079058A1 (en) 2021-11-05 2023-05-11 Yokogawa Insilico Biotechnology Gmbh Cell culture with reduced production of lactate
CA3238377A1 (en) 2021-11-15 2023-05-19 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
CA3239216A1 (en) 2021-11-23 2023-06-01 Janssen Biotech, Inc. Method of treating ulcerative colitis with anti-il23 specific antibody
US12110276B2 (en) 2021-11-24 2024-10-08 Genentech, Inc. Pyrazolo compounds and methods of use thereof
WO2023097194A2 (en) 2021-11-24 2023-06-01 Genentech, Inc. Therapeutic compounds and methods of use
EP4448179A1 (en) 2021-12-17 2024-10-23 Abbott Laboratories Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
KR20240128067A (ko) 2021-12-29 2024-08-23 브리스톨-마이어스 스큅 컴퍼니 랜딩 패드 세포주의 생성
AU2023212994A1 (en) 2022-01-28 2024-08-08 Georgiamune Inc. Antibodies to programmed cell death protein 1 that are pd-1 agonists
WO2023150652A1 (en) 2022-02-04 2023-08-10 Abbott Laboratories Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
WO2023164487A1 (en) 2022-02-22 2023-08-31 Brown University Compositions and methods to achieve systemic uptake of particles following oral or mucosal administration
TW202346322A (zh) 2022-03-02 2023-12-01 日商第一三共股份有限公司 含Ｆｃ分子之製造方法
EP4245772A1 (en) 2022-03-18 2023-09-20 Netris Pharma Anti-netrin-1 antibody to treat liver inflammation
EP4249509A1 (en) 2022-03-22 2023-09-27 Netris Pharma Anti-netrin-1 antibody against arthritis-associated pain
CN119213027A (zh) 2022-03-29 2024-12-27 奈特里斯药物公司 新型Mcl-1抑制剂以及Mcl-1与BH3模拟物例如Bcl-2抑制剂的组合
EP4253418A1 (en) 2022-03-29 2023-10-04 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Immune cells expressing chimeric antigen receptors and bispecific antibodies and uses thereof
AU2023247337A1 (en) 2022-03-30 2024-11-14 Janssen Biotech, Inc. Method of treating mild to moderate psoriasis with il-23 specific antibody
JP2025512824A (ja) 2022-04-01 2025-04-22 ジェネンテック， インコーポレイテッド 抗ｆｃｒｈ５／抗ｃｄ３二重特異性抗体による処置のための投与
JP2025511909A (ja) 2022-04-07 2025-04-16 ツインピッグ バイオラブ インコーポレイテッド Ｉｔｇｂ２媒介薬物伝達システム
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
IL316738A (en) 2022-05-11 2024-12-01 Genentech Inc Dosage for treatment with anti-FCRH5/anti-CD3 bispecific antibodies
WO2023223265A1 (en) 2022-05-18 2023-11-23 Janssen Biotech, Inc. Method for evaluating and treating psoriatic arthritis with il23 antibody
KR20250022049A (ko) 2022-06-07 2025-02-14 제넨테크, 인크. 항-pd-l1 길항제 및 항-tigit 길항제 항체를 포함하는, 폐암 치료의 효율을 결정하는 방법
KR20250035053A (ko) 2022-06-07 2025-03-11 리제너론 파아마슈티컬스, 인크. T 세포 활성을 조절하기 위한 다중특이적 분자 및 이의 용도
EP4536836A1 (en) 2022-06-07 2025-04-16 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
KR20250029905A (ko) 2022-06-27 2025-03-05 서트로 바이오파마, 인크. β-글루쿠로나이드 링커-페이로드, 이의 단백질 접합체, 및 이의 방법
EP4548100A1 (en) 2022-06-29 2025-05-07 Abbott Laboratories Magnetic point-of-care systems and assays for determining gfap in biological samples
JP2025523020A (ja) 2022-07-13 2025-07-17 ジェネンテック， インコーポレイテッド 抗ＦｃＲＨ５／抗ＣＤ３二重特異性抗体による処置のための投与
JP2025523049A (ja) 2022-07-14 2025-07-17 バイオ－テラ ソリュ－ションズ，エルティーディー． 抗Ｎｅｃｔｉｎ－４抗体及びその使用
WO2024015953A1 (en) 2022-07-15 2024-01-18 Danisco Us Inc. Methods for producing monoclonal antibodies
JP2025523752A (ja) 2022-07-15 2025-07-25 ストロ バイオファーマ インコーポレーテッド プロテアーゼ／酵素切断可能リンカー－ペイロードおよびタンパク質コンジュゲート
CN119604530A (zh) 2022-07-19 2025-03-11 基因泰克公司 用抗fcrh5/抗cd3双特异性抗体进行治疗的给药
PE20251399A1 (es) 2022-08-11 2025-05-22 Hoffmann La Roche Derivados de tetrahidrotiazepina biciclicos
AR130169A1 (es) 2022-08-11 2024-11-13 Hoffmann La Roche Derivados de tetrahidrotiazepina bicíclicos
JP2025526726A (ja) 2022-08-11 2025-08-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 二環式テトラヒドロアゼピン誘導体
KR20250048020A (ko) 2022-08-11 2025-04-07 에프. 호프만-라 로슈 아게 바이시클릭 테트라히드로티아제핀 유도체
TW202417056A (zh) 2022-08-29 2024-05-01 日商第一三共股份有限公司 包含變異Fc區域的抗體藥物結合物
JPWO2024053574A1 (cg-RX-API-DMAC7.html) 2022-09-09 2024-03-14
WO2024059708A1 (en) 2022-09-15 2024-03-21 Abbott Laboratories Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
JP2025538859A (ja) 2022-10-21 2025-12-02 公益財団法人川崎市産業振興財団 非吸着性またはスーパーステルス小胞
IL320355A (en) 2022-10-25 2025-06-01 Genentech Inc Therapeutic and diagnostic methods for multiple myeloma
KR20240066490A (ko) 2022-10-28 2024-05-16 주식회사 휴온스랩 항체-사이토카인 융합단백질 및 이의 용도
WO2024097639A1 (en) 2022-10-31 2024-05-10 Modernatx, Inc. Hsa-binding antibodies and binding proteins and uses thereof
IL321059A (en) 2022-11-22 2025-07-01 Janssen Biotech Inc Method for treating ulcerative colitis with a specific anti-IL23 antibody
WO2024118866A1 (en) 2022-12-01 2024-06-06 Modernatx, Inc. Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
WO2024133858A1 (en) 2022-12-22 2024-06-27 Julius-Maximilians-Universität-Würzburg Antibodies for use as coagulants
US20240247069A1 (en) 2023-01-13 2024-07-25 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
EP4406973A1 (en) 2023-01-27 2024-07-31 Fundació Privada Institut de Recerca de la SIDA-Caixa Antibodies and uses thereof for the treatment of infections caused by enveloped viruses
WO2024167898A1 (en) 2023-02-07 2024-08-15 Go Therapeutics, Inc. ANTIBODY FUSION PROTEINS COMPRISING ANTI-GLYCO-MUC4 ANTIBODIES AND MIC PROTEIN α1-α2 DOMAINS, AND THEIR USES
WO2024173842A1 (en) 2023-02-17 2024-08-22 Erasca, Inc. Kras inhibitors
WO2024178305A1 (en) 2023-02-24 2024-08-29 Modernatx, Inc. Compositions of mrna-encoded il-15 fusion proteins and methods of use thereof for treating cancer
WO2024180085A1 (en) 2023-02-27 2024-09-06 Netris Pharma Anti-netrin-1 monoclonal antibody for treating endometriosis and associated pains
KR20250160358A (ko) 2023-03-16 2025-11-12 인매진 피티이. 엘티디. Ilt7-표적화 항체 및 그의 용도
EP4431526A1 (en) 2023-03-16 2024-09-18 Emfret Analytics GmbH & Co. KG Anti-gpvi antibodies and functional fragments thereof
AU2024240129A1 (en) 2023-03-17 2025-10-09 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
WO2024194685A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
WO2024206126A1 (en) 2023-03-27 2024-10-03 Modernatx, Inc. Cd16-binding antibodies and uses thereof
WO2024211475A1 (en) 2023-04-04 2024-10-10 Abbott Laboratories Use of biomarkers to determine whether a subject has sustained, may have sustained or is suspected of sustaining a subacute acquired brain injury (abi)
AU2024256160A1 (en) 2023-04-20 2025-10-02 Amgen Inc. Methods of determining relative unpaired glycan content
WO2024226971A1 (en) 2023-04-28 2024-10-31 Abbott Point Of Care Inc. Improved assays, cartridges, and kits for detection of biomarkers, including brain injury biomarkers
AU2024270495A1 (en) 2023-05-05 2025-10-09 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024254455A1 (en) 2023-06-08 2024-12-12 Genentech, Inc. Macrophage signatures for diagnostic and therapeutic methods for lymphoma
WO2025024257A1 (en) 2023-07-21 2025-01-30 Genentech, Inc. Diagnostic and therapeutic methods for cancer
US20250108048A1 (en) 2023-07-31 2025-04-03 Sutro Biopharma, Inc. Sting agonist compounds and conjugates
WO2025027529A1 (en) 2023-07-31 2025-02-06 Advesya Anti-il-1rap antibody drug conjugates and methods of use thereof
WO2025038600A1 (en) 2023-08-14 2025-02-20 Amgen Inc. Methods for reducing yellow color
WO2025049272A1 (en) 2023-08-25 2025-03-06 The Broad Institute, Inc. Card9 variant polypeptide and antibodies directed thereto
TW202515903A (zh) 2023-10-12 2025-04-16 瑞士商百濟神州瑞士有限責任公司 手術前後基於抗ｐｄ－１之治療
WO2025080711A1 (en) 2023-10-13 2025-04-17 Sutro Biopharma, Inc. Dual payload antibody drug conjugates
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
TW202530255A (zh) 2023-12-15 2025-08-01 法商亞維西亞有限公司 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物
WO2025133707A1 (en) 2023-12-19 2025-06-26 Vectory Therapeutics B.V. Anti-tdp-43 antibodies and uses thereof
WO2025184208A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
US20250296998A1 (en) 2024-03-20 2025-09-25 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3180193A (en) 1963-02-25 1965-04-27 Benedict David Machines for cutting lengths of strip material
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE139258T1 (de) * 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
FR2664073A1 (fr) 1990-06-29 1992-01-03 Thomson Csf Moyens de marquage d'objets, procede de realisation et dispositif de lecture.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
ATE381614T1 (de) 1992-07-24 2008-01-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
ES2144440T3 (es) * 1992-08-18 2000-06-16 Centro Inmunologia Molecular Anticuerpos monoclonales que reconocen el receptor del factor de crecimiento epidermico, celulas y metodos para su produccion y compuestos que los contienen.
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
AU5632296A (en) 1995-04-27 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2222231A1 (en) * 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
EP2305027B1 (en) * 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
JP6071725B2 (ja) 2013-04-23 2017-02-01 カルソニックカンセイ株式会社 電気自動車の駆動力制御装置
US11284893B2 (en) 2019-04-02 2022-03-29 Covidien Lp Stapling device with articulating tool assembly

Also Published As

Publication number Publication date
JP2014185165A (ja) 2014-10-02
JP2005225884A (ja) 2005-08-25
CY1107708T1 (el) 2010-07-28
WO1998050433A2 (en) 1998-11-12
NL300335I1 (nl) 2008-04-01
JP5356287B2 (ja) 2013-12-04
ATE366747T1 (de) 2007-08-15
JP2008273986A (ja) 2008-11-13
DK0979246T3 (da) 2007-11-05
EP1878746A2 (en) 2008-01-16
ES2289779T3 (es) 2008-02-01
CA2288962C (en) 2011-08-30
JP2018076321A (ja) 2018-05-17
JP2009051861A (ja) 2009-03-12
FR08C0006I2 (fr) 2009-01-15
EP1878746A3 (en) 2011-05-25
KR100558110B1 (ko) 2006-03-10
JP2012158601A (ja) 2012-08-23
NL300335I2 (nl) 2008-06-02
EP0979246A2 (en) 2000-02-16
WO1998050433A3 (en) 1999-02-04
JP2017025064A (ja) 2017-02-02
LU91411I2 (fr) 2008-03-25
DE122008000009I1 (de) 2008-04-30
EP2332993A1 (en) 2011-06-15
PT979246E (pt) 2007-08-16
KR20010012243A (ko) 2001-02-15
HK1027114A1 (en) 2001-01-05
CY2008003I2 (el) 2009-11-04
CA2288962A1 (en) 1998-11-12
DE69838062T2 (de) 2008-01-31
JP2010150279A (ja) 2010-07-08
DE69838062D1 (de) 2007-08-23
US6235883B1 (en) 2001-05-22
JP2001523973A (ja) 2001-11-27
EP0979246B1 (en) 2007-07-11
AU7287098A (en) 1998-11-27
CY2008003I1 (el) 2009-11-04
FR08C0006I1 (fr) 2008-08-21

Similar Documents

Publication Publication Date Title
JP3757986B2 (ja) 上皮細胞増殖因子受容体に対するヒトモノクローナル抗体
US7807798B2 (en) Human monoclonal antibodies to epidermal growth factor receptor
AU2003243139B2 (en) Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
AU777918B2 (en) Human monoclonal antibodies to epidermal growth factor receptor
AU2004231235B2 (en) Human Monoclonal Antibodies to Epidermal Growth Factor Receptor
HK1157799A (en) Human monoclonal antibody to the human epidermal growth factor receptor
HK1027114B (en) Human monoclonal antibodies to epidermal growth factor receptor
HK1118833A (en) Human monoclonal antibodies to epidermal growth factor receptor
AU2011265413B2 (en) Human Anti-OPGL Neutralizing Antibodies as Selective OPGL, Pathway Inhibitors
HK1157211A (en) Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050112

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20050112

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20050318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20050719

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051007

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20051122

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20051220

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 3757986

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090113

Year of fee payment: 3

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090113

Year of fee payment: 3

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090113

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100113

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110113

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110113

Year of fee payment: 5

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110113

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110113

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120113

Year of fee payment: 6

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120113

Year of fee payment: 6

S201 Request for registration of exclusive licence

Free format text: JAPANESE INTERMEDIATE CODE: R314201

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120113

Year of fee payment: 6

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130113

Year of fee payment: 7

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130113

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130113

Year of fee payment: 7

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130113

Year of fee payment: 7

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term